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Abstract (English) 
Introduction: 
This thesis summarises the findings of a medical audit on the management of Cryptococcal 
Meningitis (CM). The study population of HIV positive adults (N = twenty five) were admitted 
during November 2009 – June 2010 to five hospitals of the Cape Winelands (East) District, 
Western Cape, South Africa. 
In the context of the HIV pandemic, CM has become the most common cause of community-
acquired meningitis, and has poor outcomes if left untreated. The South African HIV Clinician 
Society has published treatment guidelines in 2007. These guidelines have been used by the audit 
team to compile a list of measurable criteria (with set targets) to evaluate the structure, process 
and outcome of CM management. A pilot audit (2008) at the regional hospital has demonstrated 
that certain target standards were not met.  
Aims and Objectives: 
The aim was to improve the quality of the clinical care of HIV-patients diagnosed with CM in 
the Cape Winelands (East) district. The objectives included the review of the audit criteria and 
target standards, demonstrating improvement in quality of CM care at the Level 1 and 2 
hospitals, identifying new interventions based on the findings and providing recommendations to 
the health facilities. 
Methods 
In 2009, the researcher formed a new audit team, reviewed the audit criteria and held teaching 
interventions based on the national treatment guidelines. An intervention, based on the findings 
of the pilot audit, aimed at improving the clinical team’s adherence to the treatment guidelines. 
Results 
The audit identified the following areas that did not meet the target standards: the availability of 
Amphotericin B (Ampho B) and spinal manometers; the use of manometry in all initial lumbar 
punctures (LPs); completing fourteen days of the required Ampho B treatment; renal monitoring 
in patients on Ampho B; commencement of antiretroviral treatment (ART) by week four; and, 
the two-month survival figures post-diagnosis. 
Stellenbosch University  http://scholar.sun.ac.za
ii 
 
The re-audit at the Level 2 hospital highlighted the need for improved medical record keeping to 
aid the audit process. Arrangement of inpatient ART counselling happened more consistently at 
the Level 1 hospitals. Adherence to the ART target and measures to prevent Ampho B related 
morbidity is comparable to that of the Level 2 hospital. The audit has also provided insight to the 
researcher and audit team on the practical challenges of conducting a prospective data collection 
technique across different care settings. 
Recommendations 
Level 1 hospitals should continue to manage CM patients. The availability of spinal manometers 
and closer adherence to renal monitoring require attention. Formal feedback to the audit team 
and clinical teams is planned. A multimodal interdisciplinary Quality Improvement approach 
(such as an integrated care pathway) is recommended and a future re-audit is encouraged to 
assess improved adherence to the CM management guidelines. The buy-in of stakeholders 
(management, health care workers and patients), the ongoing support of an audit team and a 
committed Quality Improvement environment will allow the medical audit process to become 
ingrained in the South African public healthcare setting. 
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Opsomming (Afrikaans) 
Inleiding 
Hierdie tesis bied ‘n opsomming van die sleutelbevindinge van ‘n mediese oudit van 
Cryptokokkale Menigitis (CM) sorg. Die studie groep van MIV-positiewe volwassenes (N = vyf-
en-twintig) het binne-pasiënt behandeling ontvang gedurende November 2009 tot Junie 2010 in 
vyf hospitale van die Kaapse Wynland (Oos) distrik. 
In die konteks van die MIV pandemie het CM die mees algemene oorsaak van 
gemeenskapsverworwe meningitis geword, en het swak uitkomste indien onbehandeld. Die Suid-
Afrikaanse HIV Clinici Vereniging het in 2007 behandelingsriglyne gepubliseer. Hierdie riglyne 
het die oudit span gebruik om ‘n lys van meetbare kriteria (met teiken standaarde) saam te stel 
om die struktuur, proses en uitkoms fasette van CM sorg te evalueer. ‘n Proef oudit (2008) by die 
streekshospitaal het getoon dat sekere teiken standaarde nie behaal was nie.  
Doelstelling 
Die doelstelling was om die kwaliteit van kliniese sorg van MIV-pasiënte met CM (in die 
Kaapse Wynland (Oos) distrik) te verbeter. Die doelstelling sluit in die hersiening van die oudit 
kriteria, die bevesting van verbetering in kwaliteit CM sorg by vlak 1 en 2 hospitale, 
identifisering van nuwe ingreep-moontlikhede gebaseer op die bevindinge en die verskaffing van 
toepaslike aanbevelings aan die gesondheidsorg fasiliteite. 
Metodes 
Die navorser het in 2009 ‘n nuwe oudit span gevorm, die oudit kriteria hersien en 
opleidingsingrepe geskoei op die nasionale riglyne gefasiliteer. Opleidingsingrepe, gebaseer op 
bevindinge van die proef oudit, het ten doel gehad dat die kliniese span die nasionale riglyne 
nakom. 
Resultate 
Die oudit het die volgende areas uitgelig waar daar nie aan die teikenstandaarde voldoen was nie: 
the beskikbaarheid van Amphotericin B (Ampho B) en spinale manometers; die gebruik van 
manometrie in alle aanvanklike lumbaal punksies (LPs); voltooi van die veertien dae Ampho B 
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behandelingsteiken; nierfunksie monitoring van pasiënte op Ampho B; aanvang van anti-
retovirale behandeling teen week vier; en, die twee maande oorlewing post-diagnose syfers. 
Die opvolg oudit by die vlak 2 hospitaal bevestig die belang van verbeterde kliniese notas om die 
oudit proses te vergemaklik. Die reël van binne-pasiënt ART berading gebeur meer bestendig in 
Vlak 1 hospitale. Bereiking van die ART teiken en maatreëls om Ampho B verwante morbiditeit 
te voorkom, is vergelykbaar met die bevindinge by die vlak 2 hospitaal. Die oudit het die 
navorser en die oudit span ingelig rakende die praktiese uitdagings om ‘n prospektiewe data 
insamelingsmetode te poog in verskillende kliniese kontekste. 
Aanbevelings 
Vlak 1 hospitale kan steeds CM pasiënte versorg. Die beskikbaarheid van spinale manometers en 
deeglike nierfunksie monitering sal die behaling van teiken standaarde vergemaklik. Formele 
terugvoer aan die oudit span en kliniese span word beoog. ‘n Multimodale interdissiplinêre 
Kwaliteitsverbeterings benadering (soos ‘n geïntegreerde sorgplan) word aanbeveel en ‘n 
toekomstige oudit word aangemoedig om verbetering in toepassing van die CM riglyne te 
evalueer. Dit is belangrik om die sleutelspelers (bestuur, gesondheidswerkers en pasiënte) te 
betrek. Verder word voortgesette ondersteuning van die oudit span en ‘n toegewyde omgewing 
van kwaliteitsverbetering aanbeveel. Sodoende sal die oudit proses in Suid-Afrikaanse publieke 
sorg geintegreer word. 
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 iCP: (Integrated) Care Pathway 
 ICP: Intracranial Pressure 
 ID clinic: Infectious Diseases clinic 
 IDSA: Infectious Diseases Society of America 
 IRIS: Immune Reconstitution Inflammatory Syndrome 
 IV: Intravenous 
 MDR: Multi-drug Resistant 
 NHLS: National Health Laboratory Service 
 NYSDOH AI: New York Department of Health AIDS Institute 
 OI: Opportunistic Infection 
 OP: Opening Pressure 
 PEPFAR: United States President’s Emergency Plan for AIDS Relief 
 PTC: Pharmaceutical Treatment Committee 
 QI: Quality Improvement 
 QOC: Quality of Care 
 RH: Robertson Hospital 
 SA: South Africa 
 TB: tuberculosis 
 U&E, Mg: Urea, Creatinine and Electrolytes, Magnesium 
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 UNAIDS: Joint United Nations Programme on HIV/AIDS 
 UNICEF: United Nations Children’s Fund 
 USA: United States of America 
 WH: Worcester Hospital  
 WHO: World Health Organisation 
 
Please note the following definitions refer to the hospital level of care and associated package of 
care (as defined by the Department of Health, South Africa): 
Level 1 = District hospital 
Level 2 = Regional hospital 
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1. Introduction 
1.1 Introducing Medical Audit and Quality Improvement  
A few thoughts on Quality, Change and Life: 
“Quality is never an accident; it is always the result of high intention, sincere effort, intelligent 
direction and skillful execution; it represents the wise choice of many alternatives.” – William A 
Foster. 
1 
“Quality is the result of a carefully constructed cultural environment. It has to be the fabric of the 
organization, not part of the fabric.” – Phillip Crosby. 2 
“Quality is everyone's responsibility.” – W Edwards Deming. 3 
“What we achieve inwardly will change outer reality.” – Plutarch, c 46 – 120 AD. 4 
“The most important part of the audit cycle is making change” – Baker, quoted in a Clinical 
Audit Study Guide of the Sussex Partnership NHS trust. 
5 
“As is a tale, so is life: not how long it is, but how good it is, is what matters.” – Seneca the 
Younger, c 3 BC – 65 AD. 4 
 
Medical Audit, also known as Clinical Audit and Quality Improvement (QI) Cycle, is the centre 
of the process of Continuous Quality Improvement (CQI). Quality of Care (QOC) is one of the 
pillars of Clinical Governance, the concept that refers to the accountability of a health care 
system for ensuring the correct standard of care provided to its patients. 
6 
The net value of the audit process is that it leads to a review of clinical decision-making and, 
ultimately, to a shift in focus: making the most efficient use of resources for the patient. This 
viewpoint supports the role of quality improvement in resource-constrained settings. 
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1.2 Introducing the setting of this audit  
This medical audit focused on HIV (Human Immunodeficiency Virus)-positive adult patients 
treated for Cryptococcal Meningitis (CM) at hospitals in the Cape Winelands (East) district, 
Western Cape Province, South Africa.  
Figure 1 and 2 provide geographical orientation to the Cape Winelands district and its sub-
districts. 
 
 
 
Figure 2. The Cape Winelands 
district and its sub-districts 
7 
Figure 1.  
The Cape Winelands district,  
Western Cape Province 
7 
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Figure 3: Schematic overview of the Worcester Hospital Referral Network 
(Based on a schematic overview 
8
) 
 
Figure 3 provides a schematic overview of all the Level 1 hospitals (district hospitals) that refer 
to Worcester regional hospital (Level 2). It is important to note that there are two regional 
hospitals in the Cape Winelands district: Paarl regional hospital (in Drakenstein sub-district) 
serves the Drakenstein and Stellenbosch sub-districts (Cape Winelands: West). The Cape 
Winelands (East) district refers to the three sub-districts that are served by Worcester regional 
hospital: Witzenberg (Ceres hospital), Breede Valley (Worcester regional hospital and 
Brewelskloof Tuberculosis hospital) and Langeberg (Robertson and Montagu hospitals). 
 
 
1.2.1 Worcester regional hospital (WH), is situated in the Breede Valley sub-district 
(population: 148 623 in October 2009). Worcester hospital (266 beds) provides specialist 
services to seven Level 1 hospitals and numerous primary health care facilities of two 
health districts, Cape Winelands and Overberg. The Overberg district (Hermanus, 
Caledon, Swellendam and Bredasdorp) does not have its own regional hospital and, 
therefore, uses Worcester as its referral hospital. 
9,10
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1.2.2 Brewelskloof hospital (BH), Worcester, is a specialised tuberculosis (TB) hospital (both 
adults and children) for the Cape Winelands and Overberg districts and is one of six TB 
hospitals of the Western Cape. There are 206 beds for TB patients. This hospital is the 
designated multi-drug resistant (MDR) TB specialist centre. Four to five specialist TB 
doctors manage the TB patients in sub-acute beds with longer inpatient time than the 
acute beds found in the district and regional hospitals. 
 
Admission criteria for Brewelskloof hospital are those diagnosed patients who: 
 “are too ill to take medication at the local clinic 
 experience side effects of TB drugs 
 have resistant strains of TB 
 need injections and cannot receive it on a daily basis locally 
 have a history of defaulting treatment 
 have poor social circumstances, especially children in this situation” 11 
Due to the co-morbidity of HIV and TB, many of the patients admitted for TB treatment 
develop opportunistic infections (OIs) associated with World Health Organisation 
(WHO) stage four HIV disease. CM, an example of an OI, is also managed in the TB 
wards. 
Worcester hospital’s Family Medicine and Internal Medicine departments use one of 
Brewelskloof hospital’s wards for inpatient care (rehabilitation beds, step-down beds and 
Level 1 beds). Typically, CM patients diagnosed at Worcester hospital are admitted for 
inpatient care in this combined ward at Brewelskloof hospital. Doctors from Worcester 
hospital are responsible for the inpatient care of these patients. 
 
1.2.3 The Cape Winelands (East) district has three Level 1 hospitals:  
 Ceres hospital (CH) serves the Witzenberg sub-district (population: 100 939 in 
October 2009). The hospital (76 beds) has six generalist doctors. 
 Robertson hospital (RH) and Montagu hospital (MH) serve the Langeberg sub-
district (population: 102 097 in October 2009). RH (46 beds) has six generalist 
doctors and MH (40 beds) has two generalist doctors. 
7
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1.2.4 The burden of HIV disease in the Cape Winelands, Western Cape and South Africa is 
presented:  
 The South African National HIV Survey demonstrated an estimated HIV prevalence 
in 2008 in the Western Cape of 3.8% (South African national prevalence estimated at 
10.9% in 2008). 
12
 
 The South African Department of Health Study (2007) found an estimated HIV 
prevalence among antenatal clinic attendees in the Western Cape of 12.6% (South 
African national prevalence estimated at 28%). 
12
 
 The UNAIDS/WHO report published in July 2008 estimated a HIV prevalence of 
18.1% in those aged 15-49 years old at the end of 2007 (high and low estimates: 
15.4% and 20.9% respectively). This implies that around 5.7 million South Africans 
were living with HIV at the end of 2007, including 280,000 children under 15 years 
old. 
12
 
 The ASSA2003 (Actuarial Society of South Africa) model produced a similar 
estimate than the UNAIDS/WHO report: 5.4 million people living with HIV in mid-
2006, or around 11% of the total population. This model predicts that the number will 
exceed 6 million by 2015, by which time an estimated 5.4 million South Africans will 
have died of AIDS. 
12
 
 
1.2.5 The June 2010 data of total patients on Anti-Retroviral Treatment (ART) for each sub-
district of the Cape Winelands (East) district:  
 Breede Valley: Total Adults = 1996; Total Children = 170; Total = 2166. 
 Witzenberg: Total Adults = 1031; Total Children = 31; Total = 1061. 
 Langeberg: Total Adults = 575; Total Children = 40; Total = 615. 13 
 
In summary, CM patients are admitted for inpatient care at the hospitals of the Cape Winelands 
(East) district. This inpatient phase is required for Amphotericin B treatment. On discharge, these 
patients are managed at various ART sites and primary health care clinics in the drainage area of 
these hospitals. Generalist medical practitioners staff these facilities (except for the regional 
hospital and TB hospital). 
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1.3 Introducing Cryptococcal Meningitis  
Cryptococcal Meningitis (CM) is caused by an opportunistic encapsulated yeast, Cryptococcus 
neoformans. Cryptococcosis refers to a disseminated infection (skin, lung, meninges). Despite 
recent expansion of Anti-Retroviral Treatment (ART) programmes in developing countries, 
cryptococcosis remains a major opportunistic pathogen and a leading cause of mortality in AIDS 
patients (HIV infection causes a defective T-cell-mediated immunity, which leads to 
opportunistic infections). 
14 
 
CM has become the leading cause of community-acquired meningitis (ahead of tuberculous and 
bacterial meningitis) and has a significant mortality if not treated correctly (especially in the first 
two weeks after diagnosis). CM accounts for 20–45% of laboratory-confirmed cases of 
meningitis in Southern Africa. 
15 
The researcher conducted an initial pilot audit (retrospective) at Worcester hospital in 2008 as 
part of an assignment for the M Med (Family Medicine) degree. The results showed areas 
requiring improvement in the management of CM cases at Worcester hospital. The audit team 
identified gaps in the knowledge of the health care professionals, especially regarding the 
diagnosis and management of raised intracranial pressure (see summary of results in Addendum 
B). These conclusions and recommendations are applicable to CM management in the district 
(by extrapolation). These are the highlights of the findings from the pilot audit: 
 Fourteen patients’ records were reviewed and assessed according to  target standards set 
by the audit team 
 Target standards for completing 14 days of Amphotericin B and 8 weeks of high dose 
Fluconazole were met in this period (June 2007 until July 2008) 
 Opening pressures (manometry) with lumbar punctures were done in only  3 out of the 14 
patients 
 No cases of Amphotericin B associated renal impairment were found (adequate IV Saline 
pre-hydration should prevent this adverse event) 
 All the patients were referred for ART commencement, but none of the patients was 
commenced by the target standard (4 weeks from onset of antifungal treatment). 
 Adherence to long term Fluconazole prophylaxis was below target standard 
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By involving the medical team (doctors and nurses of the hospitals involved in the audit) in 
implementing the national guidelines on CM management, the researcher and the audit team 
aimed to achieve the following:  
 increased adherence to national guidelines, which will in effect lead to improved Quality 
of Care (QOC) 
 increased survival 
 effective diagnosis and treatment of CM-associated raised intracranial pressure (increased 
measurement of CSF opening pressures) 
 early access to ART 
 correct administration of Amphotericin B 
 improved morale of staff, patients and relatives dealing with CM 
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2. Literature Review 
2.1 Literature Review of Cryptococcal Meningitis 
2.1.1 Importance and relevance of CM as a clinical topic 
Cryptococcal Meningitis (CM) is now the leading cause of community-acquired meningitis, 
ahead of tuberculous and bacterial meningitis. It accounts for 20–45% of laboratory-
confirmed cases of meningitis in Southern Africa. 
15 
A 2009 article looked at the global burden of CM: the incidence ranged from 0.04 to 12% per 
year among persons living with HIV. Sub-Saharan Africa had the highest yearly burden 
estimate (median incidence 3.2%, 720 000 cases; range, 144 000–1.3 million). 16 
 
In a review in India, the authors note that CM is the first opportunistic infection that occurs in 
over a quarter of patients who develop AIDS. Furthermore, about 5–10% of patients with 
AIDS (CD4 lymphocyte count of <200 cells/ml) develop CM. About three quarters of 
patients have a large burden of fungal organisms, evidenced by a heavily positive 
Cerebrospinal Fluid (CSF) Indian ink preparation and very high titers of cryptococcal antigen 
in blood and CSF.
 17 
 
2.1.2 CM is an AIDS-defining disease with significant mortality 
A Ugandan article discussed the outcomes in CM management in the pre- and post-ART era, 
comparing the outcomes of North America with those of sub-Saharan Africa. The North 
American mortality rate for CM was less than 10% with administration of a combination of 
Amphotericin B (0.7–1.0 mg/kg per day), Flucytosine, and aggressive management of 
increased intracranial pressure. However, the mortality rate at 14 days in sub-Saharan Africa 
after receipt of Amphotericin B ranged from 17% to 36%, with a median duration of survival 
of about 1 month. The risk factors identified for increased mortality include delay in 
diagnosis, lack of Amphotericin B treatment, lack of ART, and greater fungal burdens. 
Furthermore, Fluconazole alone is routinely used in Africa because of its affordability and 
ease of use. However, treatment of HIV-associated CM in an African setting with 
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Fluconazole only (without Amphotericin B and ART) had a poor survival rate of less than 
5% at 6 months.
 18 
The article on global CM burden quoted an estimated case fatality of 55% in regions with 
primarily less developed countries, excluding sub-Saharan Africa, where it was estimated to 
be 70%. 
16 
 
2.1.3 South African National Guidelines for CM treatment and the importance of initial 
acute treatment phase 
The Spring 2007 edition of The South African Journal of HIV Medicine provided Guidelines 
for the Prevention, Diagnosis and Management of Cryptococcal Meningitis and 
Disseminated Cryptococcosis in HIV-infected patients. The authors stressed the importance 
of improving the initial acute management of CM, as this will maximize the patient’s 
chances of initial survival and subsequent entry into the ART programme.
 19 
The guideline committee recommended the following treatment protocol for CM in HIV-
infected patients: 
A. Completion of 14 days of the fungicidal agent, Amphotericin B (at 1mg/kg/day) (the 
intensive phase of CM management) 
B. Completion of 8 weeks of high dose treatment (400mg daily) of the fungistatic agent, 
Fluconazole (the consolidation phase of CM management) 
C. Long-term use of Fluconazole at 200mg daily (secondary prophylaxis)  
D. Measurement of opening pressures when doing Lumbar Punctures (LPs), to detect raised 
intracranial pressure (more than 20 cmH2O) and to relieve pressure with therapeutic taps 
E. Arranging a CT scan of the brain if there are focal signs, depressed level of consciousness 
or other contra-indications for a LP. 
 
2.1.4 Best CM treatment options in South Africa 
 
A comprehensive Cochrane review by South African authors investigated the best treatment 
for CM in resource-limited settings. Usually only Amphotericin B and Fluconazole are 
available in these settings. The authors were unable to recommend either Amphotericin B or 
Fluconazole as the superior drug for CM, as they could find no suitable studies in which 
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these two drugs were compared. Future research into the management of CM should focus on 
the most effective use of medications that are available in resource-limited settings. It was 
noted that Flucytosine in combination with Amphotericin B leads to faster and increased 
sterilisation of CSF compared to using Amphotericin B alone. However, Flucytosine is not 
available in many developing countries, including South Africa. The authors recommend that 
policy makers and national departments of health in these countries should consider 
procuring this drug for HIV treatment programmes. 
20
 
 
A 2008 review described studies that have started to optimise antifungal regimens and 
address the complications of raised cerebrospinal fluid pressure and cryptococcal IRIS. 
Furthermore, Amphotericin B at 1 mg/kg per day has been shown to be more rapidly 
fungicidal than the standard dose of 0.7 mg/kg per day (currently used in many SA 
hospitals). New data support the importance of combination therapy with Flucytosine. 
Amphotericin B and Fluconazole at 800mg is an alternative combination that appears 
superior to Amphotericin B alone. At a dosage of 400mg per day, Fluconazole alone is much 
less rapidly fungicidal than Amphotericin B and is associated with the development of 
secondary resistance.
 14 
 
2.1.5 Prevention of Amphotericin B associated renal impairment and electrolyte 
disturbance 
The guidelines in the SA Journal of HIV Medicine recommend prehydration with normal 
saline (containing added potassium) to prevent Amphotericin B-associated nephrotoxicity 
(usually occurring in the second week of therapy) and electrolyte abnormalities. Baseline and 
twice-weekly monitoring of creatinine, potassium and magnesium is appropriate. If the 
creatinine level doubles, one should consider omitting a dose of Amphotericin B or 
increasing prehydration to one litre eight-hourly. However, if the creatinine level remains 
elevated, one should stop Amphotericin B and use Fluconazole alone.
 19 
2.1.6 Importance of diagnosing and treating CM-associated raised intracranial pressure  
A seminal article, referred to as the “Graybill Paper”, highlighted the importance of raised 
intracranial pressure in CM. In this study, patients with opening pressures >25 cm H2O were 
associated with higher titers of cryptococcal capsular polysaccharide antigen in CSF, more 
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frequently positive Indian ink smears of CSF and more frequent headache, meningism, 
papilloedema, hearing loss, and pathological reflexes. Patients with pretreatment opening 
pressure <25 cm H2O had increased short-term survival compared with those with higher 
pressure. The authors conclude that opening pressures >25 cm H2O should be treated with 
large-volume CSF drainage.
 21 
A study published in 2009 (set in Thailand and South Africa) highlights the necessity of 
access to manometers to enable diagnosis and treatment of raised pressures. The authors 
conclude that aggressive management of raised opening pressure through repeated CSF 
drainage appeared to prevent any adverse impact of raised opening pressure on outcome in 
patients with CM. Their results support increasing access to manometers in resource-poor 
settings and routine management of opening pressure in patients with CM. 
22 
 
2.1.7 Optimal timing of ART initiation 
Evidence for the optimal timing of ART requires further research. The 2008 review noted 
that early mortality in developing countries is exceptionally high in those patients awaiting 
commencement of ART, or in those recently started on ART. Their data, coupled with 
evidence from a randomized trial of immediate vs. deferred ART in the setting of acute 
AIDS-related opportunistic infections (13% of which were CM), argue for earlier ART.
 14 
 
The treatment guidelines from the SA Journal of HIV Medicine noted that there is limited 
evidence for the optimal timing of ART initiation. The guideline committee believes that 
ART should be started 2 – 4 weeks after commencing treatment for CM. Although no 
prospective evidence existed in this regard, they felt that delaying ART introduction beyond 
4 weeks to reduce the risk of IRIS may increase the risk of mortality in these patients with 
advanced immunosuppression. The long in-hospital stay associated with Amphotericin B 
therapy should be used to facilitate pre-ART counselling, identification of a treatment 
supporter and early referral to an ART clinic.
 19 
 
2.1.8 CM management in the context of the EDL and Package of Care for Level 1 and 
Level 2 hospitals 
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The 2006 edition of Standard treatment guidelines and Essential Drugs List for South Africa 
– Hospital Level, Adults describes the management of Cryptococcosis in section 10.1.2 (p. 
168). 
23 
The importance of therapeutic lumbar punctures in managing elevated intracranial 
pressure is emphasised. Patients with focal neurological signs require referral for specialist 
evaluation at the next level of care (Level 2). Amphotericin B is available on the District 
Hospital Code List. This indicates that the setting of a Level 1 hospital is appropriate for CM 
management (antifungal drugs are available). 
 
In summary, the literature review showed that CM is the most common cause of meningitis in 
SA. At least 50% of CM cases have raised intracranial pressure on diagnosis. Effective treatment 
of increased pressure can improve outcome. The SA HIV Society Guidelines recommend the 
initiation of ART within two to four weeks from start of antifungal treatment for CM. The first 
two weeks are the most important phase of the treatment of CM, as this period has the biggest 
impact on outcome. 
 
2.2 Literature Review: Medical Audit and Quality Improvement  
Medical Audits (also called Clinical Audits) and Evidence Based Medicine (EBM) share a 
common history. “EBM is the explicit use of the best available evidence to inform decisions 
about the care of individual patients. ... QI (Quality Improvement) research seeks to implement 
in routine practice the processes and outcomes of care established by the best available 
evidence.” 24 
The following definition of clinical (medical) audit is endorsed by the National Institute of 
Clinical Excellence (NICE), United Kingdom: 
“Clinical audit is a quality improvement process that seeks to improve patient care and outcomes 
through systematic review of care against explicit criteria and the implementation of change. 
Aspects of the structure, processes, and outcomes of care are selected and systematically 
evaluated against explicit criteria. Where indicated, changes are implemented at an individual, 
team, or service level and further monitoring is used to confirm improvement in healthcare 
delivery.” 25 
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Importantly, the audit forms part of a continuous process. A cycle or spiral illustrates the process 
of a medical audit. An appropriate climate or environment that supports the idea of “change for 
the better” is needed in order for this process to succeed. This necessitates the buy-in of key 
stakeholders: the public/patients, the clinical personnel and the health system management. A 
paradigm shift is required in terms of the climate of the organisation or health system: from a 
“culture of blame” to a culture where the best quality of care for the patient is sought, without 
fear of retribution or victimisation. 
26 
 
A landmark report, The Report of the Public Inquiry into Children’s Heart Surgery at the Bristol 
Royal Infirmary 1984-1995, was “written as a demand, on the behalf of patients, for change in 
the culture of the Service both within the NHS (National Health Service, United Kingdom) itself 
- how professionals behave towards each other - and also in the way that individual professionals 
treat their patients”. This report argued for a change in organisational culture: “The culture of the 
future must be a culture of safety and of quality; a culture of openness and of accountability; a 
culture of public service; a culture in which collaborative teamwork is prized; and a culture of 
flexibility in which innovation can flourish in response to patients’ needs.” 27 
 
The South African Department of Health has also targeted the concept of establishing an 
“environment in which quality health care will flourish”. A Policy on Quality in Health Care for 
South Africa suggests four methods to enable the establishment of such an environment: 
28 
 
i. “Strengthening the hand of the user”: empowering the patient population with the 
necessary information to make the correct decision on their health care 
ii. “Focusing on equity of health care and vulnerable populations”: to address the disparities 
in health resources and quality of care between different individuals and communities 
iii. “Promoting public/private partnerships and the accountability of both sectors for quality 
improvement”: a coordinated effort is required to improve quality of care, whereby the 
views and expertise of stakeholders in both sectors should be incorporated 
iv. “Reducing errors and increasing safety in health care”: an adverse events reporting 
system will help to enable system changes. 
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The report suggests steps to build the capacity to improve quality. These steps include: fostering 
evidence-based practice and innovation, adapting organisations for change; engaging the “health 
care workforce”; providing the necessary training and building the information systems’ capacity 
to measure quality improvements. 
Page 21 of the report explains the role of clinical audit: 
28 
“Clinical audit is essential in patient care as it brings together professionals from all divisions of 
health care to: 
i. Consider clinical evidence (evidence-based health care); 
ii. Promote education and research; 
iii. Develop and implement clinical guidelines; 
iv. Enhance information management skills 
v. Contribute towards better management of resources.” 
 
Importantly, this report makes it clear that, “All health professionals at all levels of care will 
participate in clinical audit.” 28 
 
The tasks of clinical audit teams include: 
i. “Determine what aspects of current work are to be considered for auditing; 
ii. Describe and measure present performance and trends; 
iii. Develop standards, if these are not available; 
iv. Decide what needs to be changed; 
v. Negotiate change; 
vi. Mobilise resources to effect change; and 
vii. Review and renew processes.” 
 
The report describes the ethos in which quality improvement may flourish: “a standardised 
managerial model will be developed to prevent the clinical audit and peer review process 
developing into a search for error only, which could lead to the denigration and condemnation of 
others.” 28 It should not be a witch-hunt, but the emphasis should be on joining efforts for the 
common goal of improving the standard of care, and embracing the organisation’s learning 
curve.
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This idea is supported in a presentation by prof JV van der Merwe, Medical Advisor to Council 
for Medical Schemes, South Africa: 
“For CLINICAL GOVERNANCE to be successful, health organisations must demonstrate the 
following features: 
i. An open and participative culture 
ii. A commitment to quality that is shared by staff and managers 
iii. A comprehensive programme of quality improvement systems” 29 
 
The foreword of Principles for Best Practice in Clinical Audit (published by National Institute of 
Clinical Excellence, UK), provides an eloquent summary of the pivotal role of the medical audit: 
“Clinical audit is at the heart of clinical governance. 
i. It provides the mechanisms for reviewing the quality of everyday care provided to 
patients with common conditions like asthma or diabetes. 
ii. It builds on a long history of doctors, nurses and other healthcare professionals 
reviewing case notes and seeking ways to serve their patients better. 
iii. It addresses quality issues systematically and explicitly, providing reliable 
information. 
iv. It can confirm the quality of clinical services and highlight the need for 
improvement.” 25 
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2.3 Literature Review: Medical Audit of Cryptococcal Meningitis 
Management 
The researcher conducted a search on internet-based search engines: Google, Google Scholar and 
PubMed (http://www.ncbi.nlm.nih.gov/) and found a limited number of publications with the 
search terms of “Cryptococcosis”, “Cryptococcal Meningitis”, “audit” and “quality 
improvement”. 
2.3.1 An online PowerPoint presentation (on the website of the Department of Family 
Medicine of the Pietermaritzburg and Midlands Complex, South Africa) discussed the 
process of quality improvement and presented the findings of a CM audit at Northdale 
hospital, a district hospital in Pietermaritzburg, uMgungundlovu health district, 
KwaZulu-Natal, South Africa. 
30 
This hospital serves a population of about 200 000. 
31
 
The motivation for this audit was recurrent readmissions for CM and varying length of 
stays and patient outcomes. The audit team consisted of the Clinical Head in the Family 
Medicine department, the Principal Family Physician, the Chief Family Physician, the 
Laboratory Microbiologist, the Principal Specialist in Infectious diseases, the Infection 
Control Practitioner and the Medical Ward unit manager. The audit team reviewed the 
clinical team’s current practice of eighteen CM cases that were diagnosed during July 
2006 at Northdale hospital.  
The key findings were a follows: 
i. Problems faced regarding managing CM-associated raised intracranial pressure 
(ICP): not measuring CSF opening pressures, no available spinal manometers, not 
recognising headache caused by raised ICP. 
ii. Problems faced regarding general CM management: uncertainty regarding 
management protocol and when to discharge, failure to educate patients and family, 
uncertainty regarding management of CM re-admissions (especially regarding the 
need to repeat a diagnostic lumbar puncture). 
iii. Problems faced regarding follow-up at Anti-Retroviral Treatment clinics and long-
term Fluconazole management and adherence. 
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The key recommendations were as follows: 
i. Addressing resource needs (manometers) 
ii. Importance of ART clinic and CM management partnership 
iii. Importance of diagnosing and treating raised ICP 
iv. Addressing the need to develop a local CM treatment guideline 
The presenter highlighted the Framework for the Quality Improvement Process (Figure 4) 
30 
 
 
2.3.2 In a report (2005) from two hospitals in Washington, DC, United States of America 
(USA), researchers emphasised the importance of adherence to guidelines for CM 
management. 
32
 The Infectious Diseases Society of America (IDSA) published these 
guidelines in 2000. 
33
 Although the terms “clinical/medical audit” or “quality 
improvement” were not used in this report, it could be seen as the first step of a quality 
improvement process: reviewing current practice against evidence-based guidelines. This 
study sought to assess the level of adherence with the guidelines and to describe the 
impact that deviation from these recommendations may have on clinical outcomes. 
The researchers conducted a retrospective review of thirty-nine consecutive patients with 
cases of culture-proven, community-acquired meningitis. Twenty-six (67%) of these 
patients were diagnosed with CM. Cerebrospinal fluid opening pressure had been 
measured in thirteen (50%) of these twenty-six patients, and “major deviations from the 
Figure 4 
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guidelines” with respect to raised ICP management were observed in fourteen patients 
(54%). “Major deviations” were defined as failure to measure the opening pressure with 
the initial lumbar puncture and/or failure to attempt to lower the ICP within 72 hours 
after the CSF pressure was measured to be more than 35 cm H2O. Seven (50%) of these 
fourteen patients developed “neuropathies” (new or worsening cranial nerve deficit, 
confusion, hallucinations, or obtundation) during therapy, compared with one of the five 
patients whose care had minor or no deviations from the guidelines. 
 
2.3.3 International examples of general QI projects in the HIV arena include: 
 
2.3.3.1 HIVQUAL (HIV Quality of Care) is a United States of America (USA) model for 
building capacity for quality management that was designed to improve care for people 
living with HIV. 
34
 Originally, the New York State Department of Health AIDS Institute 
(NYSDOH AI) in partnership with the HIV/AIDS Bureau of the USA Health Resources 
and Services Administration (HRSA) developed this model. The National Project was 
launched in 1995 and has now expanded to over 200 sites in the USA. 
This model consists of three key elements:  
i. Quality improvement 
ii. Performance measurement 
iii. Infrastructure and capacity building 
HIVQUAL International (HIVQUAL-I), modelled after the New York programme 
(HIVQUAL), was started in 2003 in Thailand, and has since expanded to Uganda, 
Mozambique, Namibia, Nigeria, Haiti, Guyana, Kenya, Botswana, Rwanda, Vietnam and 
Swaziland. The HIVQUAL model has been successfully adapted in these countries, 
adjusting for differences in guidelines, resources and healthcare models. Central to the 
HIVQUAL approach to quality management is the emphasis on the development of 
systems and processes to support quality improvement activities, which involve clinic 
staff and patients, with support from HIVQUAL programme leadership. Structural 
features are designed to be sustainable. HIVQUAL-I is supported by the Office of the 
Global AIDS Coordinator (OGAC), the Centre for Disease Control (CDC) Global AIDS 
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Programme (GAP) Office in each country, where the project is integrated into the 
national AIDS programme. 
HIVQUAL-I is also supported through HRSA as the International Quality Center for 
USA President’s Emergency Plan for AIDS Relief (PEPFAR) and through funding from 
United Nations Children’s Fund (UNICEF). 
 
2.3.3.2 Thailand’s programme, HIVQUAL-T, aims to develop a comprehensive HIV care model 
in Northern Thailand. Several governmental and non-governmental partners are involved 
in this Quality Improvement process. A dedicated QI budget, nation policy, consultant-
led audit teams and group-learning meetings support this system. 
35
 
2.3.3.3 In the USA, the New York Department of Health AIDS Institute’s (NYSDOH AI) 
National Quality Center, in partnership with the Health Resources and Services 
Administration’s (HRSA) HIV/AIDS Bureau (HAB) developed a comprehensive guide 
(2008): Guideline-based Quality Indicators for HIV Care. 
36
 This guide contains 
performance measures that “represent not just what constitutes good medical 
therapeutics, but also reflect the comprehensive package of services that is critical for 
providing the best possible care to patients with HIV”.  
A panel of clinical experts developed this quality improvement resource, which provides 
eleven sets of HIV-specific performance measures. The measures can be adapted by HIV 
programmes and contribute to providing the highest standards of care to HIV-infected 
patients. These indicators are categorised within the following aspects of HIV care and 
treatment: HIV primary care, perinatal care, tuberculosis, sexually transmitted diseases 
(STD), hepatitis, prevention, mental health, substance use, occupational post-exposure 
and oral health. Performance measures for opportunistic infections are also included.  
These performance measures are aimed at busy health care workers and provide access to 
evidence-based HIV-specific indicators. Each measure is described by citing relevant 
guidelines, scientific background information and detailed indicator definitions. These 
indicators allow health care workers to measure the quality of the care provided. The 
performance data should then be used to improve key aspects of HIV care (implement 
change). 
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The measures for CM are provided in the format used throughout the document:  
i. “Eligible Population: All HIV-infected patients 
ii. Denominator Description: Number of HIV-infected patients with cryptococcal 
meningitis 
iii. Numerator Description: Number of patients with cryptococcal meningitis who 
received therapy with at least 2 weeks of an amphotericin B preparation, followed 
by at least 22 weeks of fluconazole.” 36 
Reporting of these indicators is not required, nor is national reporting systems for these 
indicators in place. This differs from the HIVQUAL indicators, that are reviewed 
annually and revised accordingly, and are the standardised measures for reporting the 
quality of HIV care by HIV ambulatory care programmes participating in the USA 
HIVQUAL programme. 
 
In summary, the topic of Quality Improvement is not new to the HIV context. However, a search 
of the published literature showed a limited number of CM specific medical audits. It is 
important to focus on the quality of comprehensive care, but the value of quality management of 
specific opportunistic infections (such as CM) needs emphasis. 
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3. Aim and Objectives 
3.1 Aim: This medical audit aimed to improve the quality of the clinical care of Human 
Immunodeficiency Virus (HIV)-patients diagnosed with Cryptococcal Meningitis (CM) in the 
Cape Winelands (East) district by evaluating the clinical team’s awareness of and adherence to 
national treatment guidelines following the interventions proposed by the findings of the pilot 
audit.  
3.2 The Objectives of the audit on the quality of care for CM in Level 1 and 2 hospitals 
were: 
a. To review existing and create new appropriate target standards for the management 
aspects of CM 
b. To demonstrate an improvement in the quality of CM care at the Level 2 hospital, 
considering the effect of the intervention after the pilot audit 
c. To identify strengths and weaknesses in the quality of CM care at Level 1 and Level 2 
hospitals  
d. To reflect on the quality of CM care at Level 1 compared to Level 2 hospitals 
e. To identify key interventions that may improve the quality of care of CM patients 
f. To provide recommendations to the facilities and department of health 
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4. Methods 
4.1 Study Design Choice and Rationale: 
Medical/Clinical Audit (Quality Improvement cycle). Audit is about monitoring performance 
against established standards, and implementing appropriate change, as necessary, to meet these 
standards. Continuous Quality Improvement is an important aspect of the process of clinical 
governance: it involves both the critical application of research evidence and the formal 
evaluation of that application in the form of an audit.  
The initial pilot audit in 2008 (the Worcester hospital experience) revealed that certain important 
target standards have not been met. The findings provided sufficient motivation to continue the 
audit cycle. A list of recommendations was compiled and these were used to educate the health 
care team (implementation of the intervention), before the researcher and the audit team 
commenced the subsequent audit cycle in the larger geographical area: the eastern part of the 
Cape Winelands district (Brewelskloof, Ceres, Montagu, Robertson and Worcester hospitals).  
There are advantages to involve the district hospitals in the Cape Winelands (East) district in the 
audit: larger study population; reaching and educating a larger number of health professionals 
about the latest national guidelines; identifying issues unique to managing CM in the district 
hospital setting. 
4.2 Evidence base 
The guidelines for the management of CM (for the purpose of this audit) are those published in 
the Spring 2007 edition of The South African Journal of HIV Medicine (Official Journal of the 
South African HIV Clinician Society): Guidelines for the Prevention, Diagnosis and 
Management of Cryptococcal Meningitis and Disseminated Cryptococcosis in HIV-infected 
patients.
 19 
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4.3 Timeframe of Audit 
The timeframe consisted of five phases: 
i. Team formation and setting of new criteria: September and October 2009 
ii. Implementation of changes to improve the quality of care: September and October 2009 
iii. Collect data: November 2009 – June 2010 
iv. Analysis of data: July – August 2010 
v. Reflection and planning of new changes: July – August 2010 
4.4  The method reflects the steps of the audit cycle, starting with the intervention 
following the pilot audit: 
Figure 5: Copy of PowerPoint Slide used in Teaching Intervention: the Quality 
Improvement Cycle 
Involve the
practice team
Choose topic
Agree criteria
set target standards
Observe practice
collect data
Evaluate information
performance versus targets
Plan care
implement change
Medical Audit = Quality Improvement
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4.4.1 Step 1: Intervention: plan changes based on findings of the previous pilot audit  
The main intervention based on the findings of the pilot audit was the education of the health 
professional team treating CM patients at the hospitals in this district. The team was educated on 
the correct treatment of CM (based on the national guidelines compiled by the SA HIV Clinician 
Society in 2007). 
19 
Teaching activities formed the basis of the educational intervention. During September and 
October 2009, the researcher arranged a meeting at each hospital involved in the audit. Figure 5 
shows a slide from the PowerPoint presentation used.  
A one hour-long interactive teaching session was held at Worcester hospital on 30 October 2009. 
All health care personnel of the departments of Internal Medicine, Family Medicine and the ART 
clinic were invited. Fifteen people (including the researcher) attended the session. The 
crossover/jigsaw small group technique was used which involves two phases:  
Phase 1: Four Expert Groups (each with a facilitator) discussed the following topics: 
 A: LP and Spinal Manometry  
 B: Amphotericin B use and pre-cautions 
 C: Medical Audit practicalities (including review of criteria and target standards) 
 D: ART work-up and follow-up 
During Phase 2, a member of each Expert Group reconvened to form a Home Group: each 
person had to present a summary of the discussion in the individual Expert Groups. This 
technique promotes active participation and learning. 
 
 
 
 
 
 
 
 
 
 
Figure 6: The Home Group 
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The One Minute Paper (a classroom assessment technique) was used to obtain feedback from the 
group. One open question was asked: “Regarding the management of Cryptococcus Meningitis 
patients: which aspect of your management of these patients will change after today’s 
discussion?” Addendum 2 shows the feedback from the attendees.  
Similar educational sessions were conducted at the other hospitals involved in the audit. 
These teaching activities had two main goals: to introduce the planned audit (and the concept of 
improving QOC via an audit) and to recruit members for the audit team; and, to familiarise the 
team with the CM treatment guidelines. The educational presentation focused on the problem 
areas identified by the pilot audit, specifically: the correct administration of Amphotericin B, the 
appropriate use of spinal manometry and the need for fast-tracking ART counselling and 
initiation. The importance of adhering to the national treatment guidelines during the first two 
weeks of management was emphasised. This “A2A” (Ampho B to ART) period may have the 
greatest impact on the mortality associated with CM. 
Structural interventions entailed ordering and stocking of spinal manometers (by involving the 
hospital management). The researcher distributed posters and handouts describing the CM 
treatment guidelines (see Addenda 3, 4 and 5: these documents were part of the standard set of 
audit documents, including a poster and printed guidelines, that was distributed by the researcher 
at each hospital involved in the audit). The poster (Addendum 6) was included in the Spring 
2007 edition of the The South African Journal of HIV Medicine. 
19 
The researcher obtained 
permission from the publisher to replicate the posters for distribution in the hospitals. 
Furthermore, the researcher and the audit team liaised with the ART clinics to ensure “fast-
tracking” of the ART counselling and introduction process. The ART clinicians were invited 
onto the audit team. 
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4.4.2 Step 2: Create a new audit team 
The clinical audit team of the Cape Winelands (East) sub-district consisted of the researcher, the 
Clinical Programme Coordinator: Infection Prevention and Control, as well as key individuals 
(audit champions) from the sub-districts, who represent their hospital’s audit team. Involvement 
and cooperation of all relevant health care personnel (managers, doctors, nurses, pharmacists, 
laboratory technicians, ART clinic personnel) was recommended in order to ensure a successful 
audit process. 
4.4.3 Step 3: Revise old and develop new criteria and target standards  
The researcher involved the audit team to formulate the target standards for each criterion of the 
CM management process. 
“The target standard of care is the result of a well-defined and measurable criterion, as well as a 
level of performance for that criterion.” 38 
The criteria selected represent the three audit areas of Structure, Process and Outcome. Listed 
below are the criteria. The level of performance (target standard) for each criterion is provided in 
Table 1. The target standards for the initial pilot audit at Worcester hospital were developed in 
2008. The researcher compiled the list of criteria after a thorough literature review and after 
discussion with both the Physician and the Family Physician at Worcester hospital. 
The researcher and the audit team revised existing criteria and included new criteria prior to the 
new audit cycle. The new/modified criteria appear in Bold in Table 1. 
In the pilot audit, Adherence to long-term Fluconazole (secondary prophylaxis) was included as 
a criterion. The researcher removed this criterion from the audit, as the criterion was difficult to 
measure due to paucity of post-discharge information (short period of follow-up). The HIV 
Clinician Society of South Africa recommends the following secondary prophylaxis regime (to 
prevent recurrences of CM): Fluconazole 200mg daily for life (or until CD4 > 200cells/μl for 
more than 6 months on ART, at least 12 months’ Fluconazole in total). 19 (The Level of 
Performance for the criterion in the pilot audit was 80%, as patient, socio-economic, disease or 
health system-related factors could prohibit total adherence.) 
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Table 1 References: The source of evidence for each criterion’s target standard is shown in 
the table.  
The audit team reached consensus for two of the outcome criteria using the following two 
references (see Table 1: Criteria 3.3 and 3.4) 
x. Drug information on Ampho B listed thrombophlebitis in the group of adverse events that are 
typically found in 10% (or more) of patients exposed to the drug. 
39, 40 
y. An article from Uganda on the outcomes in CM management in the pre- and post-ART era 
mentioned Sub-Saharan mortality figures of up to 36%. 
18 
The researcher and audit team would 
like to see that six out of ten patients (60%) diagnosed with CM are still alive two months after 
diagnosis, as the same treatment protocol is used. 
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Table 1: Audit Criteria (New/modified criteria are highlighted in Bold) 
Target: 
Level of 
Performance 
Source of 
Evidence 
1.Structure 1.1 Availability of Amphotericin B 
100% 
Audit Team 
Consensus 
  
This drug should be available in the wards to avoid delay in starting fungicidal treatment 
of fourteen days 
 
  1.2 Availability of Fluconazole 
100% 
Audit Team 
Consensus 
  
This drug should be available to continue with the consolidation phase after completion 
of the Amphotericin B course.  
 
  
1.3 Protocol (Poster and treatment guidelines) for the administration of Amphotericin B 
in wards 
100% 
SA HIV Clinician 
Society Guidelines 
and Audit Team 
Consensus 
  
Nursing professionals and doctors should know how to prepare the Amphotericin B 
solution and how to administer it correctly. The researcher provided a set of posters and 
treatment guidelines to each hospital prior to commencement of the data collection 
period. 
 
  1.4 Availability of Spinal Manometers 
80% 
SA HIV Clinician 
Society Guidelines 
  
Spinal Manometers should be available when performing Lumbar Punctures (LP’s) on 
CM patients (availability may vary, as certain hospitals had to order manometers for the 
first time prior to this audit) 
 
2.Process 2.1 CT scan if depressed Level of Consciousness/Focal Neurology 
100% 
SA HIV Clinician 
Society Guidelines 
  
In those patients with a depressed GCS (Glasgow Coma Scale < 15/15) or any focal 
neurological signs (i.e. where a LP would be contra-indicated), a CT scan of the brain 
should be requested.  
 
  2.2 Use of CSF manometry in all initial LP’s  
100% 
SA HIV Clinician 
Society Guidelines 
  
All patients who require a LP should have their initial CSF opening pressure measured. 
Early diagnosis of raised CSF pressure (>20 cmH2O) would facilitate early therapeutic 
taps and improve outcome. 
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Table 1: Audit Criteria (New/modified criteria are highlighted in Bold) 
Target: 
Level of 
Performance 
Source of 
Evidence 
  
2.3 Follow-up Manometry post-CM diagnosis when raised opening pressure (OP) with 
initial LP or symptoms of raised ICP 
80% 
SA HIV Clinician 
Society Guidelines 
  
In those patients diagnosed with CM, a follow-up manometry should be performed if an 
initial OP was raised or if the patient had symptoms of raised ICP. 
  
(Problems with availability of manometers may hamper this process. The researcher and 
audit team would like to see that the current practice reaches this target; the target may 
be changed to 100% for future practice.) 
 
  2.4 Requesting CLAT on Indian ink-negative CSF samples 
100% 
SA HIV Clinician 
Society Guidelines 
  
If the initial Indian ink stain (available at the local NHLS Laboratory in Worcester) on 
the CSF specimen is negative, a CLAT (Cryptococcus Latex Antigen Test) should be 
requested. This test is done at the National Health Laboratory Service (NHLS) 
Laboratory in Greenpoint, Cape Town (not available at the local NHLS Laboratory in 
Worcester).  
  2.5 Completing target of fourteen days of IV Amphotericin B 
80% 
SA HIV Clinician 
Society Guidelines   
The accepted duration of treatment for IV Amphotericin B in HIV-positive patients in 
fourteen days (two weeks) – this is the initial or induction phase of antifungal treatment 
where a fungicidal drug is used. 
  
(Level of Performance = 80% ; a minimum duration of treatment equals seven to ten 
days) 
  2.6 Using correct dose of Amphotericin B (1mg/kg) 
100% 
SA HIV Clinician 
Society Guidelines 
  
The accepted dose of Amphotericin B is 1mg/kg, when used without Flucytosine . 
Previously, a dose of 0,7mg/kg has been used widely. This dose was intended for use in 
combination with Flucytosine. However, Flucytosine is not currently available in South 
Africa. 
  
2.7 Average number of U&E, Mg tests whilst on Amphotericin B  
(initial and two/week) 
100% 
SA HIV Clinician 
Society Guidelines 
and Audit Team 
Consensus 
  
During the standard fourteen-day Amphotericin B treatment period, an average of five 
U&E and Mg tests should be performed on each patient (one initial value and two tests 
per week, if no abnormal findings – with abnormal test results, the tests should be 
performed more often). 
Stellenbosch University  http://scholar.sun.ac.za
30 
 
Table 1: Audit Criteria (New/modified criteria are highlighted in Bold) 
Target: 
Level of 
Performance 
Source of 
Evidence 
  2.8 Saline preload prior to daily Amphotericin B dose 
100% 
SA HIV Clinician 
Society Guidelines 
  
A liter of normal saline (with one ampoule of 20 mmol KCl) should be administered 
daily prior to the daily Amphotericin B dose. This helps to prevent Amphotericin B 
associated renal impairment and hypokalaemia. 
 
  2.9 Saline IV flush after daily Amphotericin B dose 
100% 
SA HIV Clinician 
Society Guidelines 
  
The IV access of each patient should be flushed with normal saline after completion of 
the daily Amphotericin B dose. This simple procedure reduces the risk of Amphotericin 
B associated thrombophlebitis. 
 
  2.10 Referral for inpatient ART counselling 
80% 
SA HIV Clinician 
Society Guidelines 
  
“the long in-hospital stay associated with Amphotericin B therapy should facilitate pre-
ART counselling, identification of a treatment supporter and early referral to an ART 
centre”. 19 
 
  2.11 High dose Fluconazole for eight weeks (consolidation phase) 
100% 
SA HIV Clinician 
Society Guidelines 
  
The accepted duration of the consolidation phase is eight weeks, where the fungistatic 
drug, Fluconazole is used at the dose of 400mg daily. 
 
  2.12 Referral to ART clinic 
100% 
SA HIV Clinician 
Society Guidelines 
  
CM is an AIDS-defining disease and referral for ART treatment is indicated.  
 
3.Outcome 
 
3.1 Commencement of ART by week four into antifungal treatment 
80% 
SA HIV Clinician 
Society Guidelines 
and Audit Team 
Consensus 
  
 
“Evidence for the optimal timing of ART initiation is not available: we believe ART is 
most appropriately started 2 – 4 weeks after treatment for [cryptococcosis] has 
commenced. Although no prospective evidence exists in this regard, given these 
patients’ advanced immunosuppression, delaying ART introduction beyond 4 weeks to 
reduce the risk of IRIS may increase the risk of mortality.” 19 
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Table 1: Audit Criteria (New/modified criteria are highlighted in Bold) 
Target: 
Level of 
Performance 
Source of 
Evidence 
  3.2 Morbidity: incidence of Amphotericin B associated renal impairment 
20% 
SA HIV Clinician 
Society Guidelines 
  
Major side-effects of Amphotericin B include renal impairment due to renal tubular 
toxicity (usually in the second week of therapy). The SA Journal of HIV Medicine
1
: 
“Nephrotoxicity and electrolyte abnormalities may be prevented by prehydration with 
normal saline containing potassium. Nephrotoxicity usually occurs in the second week of 
therapy with amphotericin B; baseline and twice-weekly monitoring of creatinine, 
potassium and magnesium is appropriate. If creatinine doubles, consider omitting a dose 
of amphotericin B or increasing prehydration to 1 litre 8- hourly. If creatinine remains 
elevated, stop amphotericin and use fluconazole.” 19 
  
(Level of Performance = 20% = the audit team would like to see that only one in 5 
patients suffer from this potentially preventable complication) 
  3.3 Morbidity: Amphotericin B associated thrombophlebitis 
10% 
Audit Team 
Consensus, based 
on evidence 
x   
The risk of Amphotericin B associated thrombophlebitis is reduced by flushing the IV 
access of each patient with normal saline after completion of the daily Amphotericin B 
dose. 
  
(Level of Performance = 10% = the audit team would like to see that only one in 10 
patients suffer from this potentially preventable complication) 
  3.4 Two-month-survival post-diagnosis 
60% 
Audit Team 
Consensus, based 
on evidence 
y
 
  
The researcher wants to know the percentage of living patients two months after the 
initial diagnosis of CM was made. It should be comparable to Sub-Saharan and/or 
National Standards. 
18, 41 
  
(Level of Performance = 60% = the researcher and audit team would like to see that 6 
out of 10 patients diagnosed with CM are still alive two months after their diagnosis has 
been made. The Sub-Saharan figures mentioned, show that the mortality is up to 36%; 
therefore, the survival should be at least 60% in the Cape Winelands (East) setting, as 
the same treatment protocol is used. ) 
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4.4.4 Step 4: Collection of data to measure these target standards 
4.4.4.1 Study population: All adult (>13 years) HIV-positive patients diagnosed with 
Cryptococcal Meningitis (CM) and treated at the hospitals in the eastern part of the Cape 
Winelands District, were included into the audit. Only those patients diagnosed with CM in the 
specified period (November 2009 to June 2010) were enrolled.  
Patients with CM were diagnosed when the CSF tests for CM were positive (Indian ink test or 
CLAT). A CLAT titer of equal or greater than 1:8 was considered positive and a titer less than 
1:8 was considered negative (this was agreed on in conjunction with the clinical microbiologist 
at Greenpoint NHLS laboratory, where the CLAT tests were done, after consultation with the 
package insert of the CLAT test in use).  
The treatment guidelines for HIV-positive and HIV-negative patients differ substantially. CM is 
a rare diagnosis in HIV-negative patients (typically, there is another source of immune 
suppression, as CM is an opportunistic infection). Only HIV-positive patients were included in 
the audit. 
4.4.4.2 Data source: A prospective data collection process was planned: the team would start to 
collect the data on diagnosis and continue during the period of care, but the data analysis would 
start only after the completion of the data-capturing period. 
This data collection plan included a confidential data-capturing sheet, that was to be completed 
on admission (see data capturing sheet in Addendum 3) and kept up to date during the pre-
determined follow-up period (admission, inpatient stay, discharge, ART clinic follow-up). The 
audit team had to notify the researcher (audit lead) of every patient on discharge (a unique CMA 
number was supplied to each case, in order to ensure confidentiality). The researcher kept the list 
of cases with their respective identifiable data in a secure place.  
The researcher and the audit team experienced practical difficulties with the planned prospective 
data collection process. The Level 1 hospitals were adherent to the data collection procedure, but 
the researcher received no completed data capturing forms from the Level 2 hospital. The 
researcher contacted senior members of the Level 2 hospital’s clinical team to remind them of 
the audit during the data collection period.  
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To address case underreporting due to non-adherence to the data collection method, the 
researcher arranged with the National Health Laboratory Service (NHLS) laboratory to obtain a 
list of all CM-related tests from November 2009 until June 2010. 
After using the official application process, the NHLS laboratory sent the researcher an Excel 
Pivot Table with a list of patient folder numbers of all Cryptococcus-related tests requested 
during the period of November 2009 until June 2010 at the hospitals included in the audit. The 
only identifiable patient details were the patient folder numbers. These were used in a 
confidential manner. This NHLS-generated list identified 55 patients with positive CM-related 
tests (including those with a CLAT titer < 1:8). 
The following criteria determined the audit study population. All cases that met the criteria were 
included in the audit. No sampling was done. 
4.4.4.3 CM Audit Inclusion criteria: 
 HIV positive 
 Adult (age > thirteen years) 
 CM (CLAT and/or Indian ink positive; CLAT titer ≥ 1:8 on CSF) 
 Hospital clinical records available 
 Admission to a hospital of the Cape Winelands (East) district and/or diagnosis of CM at a 
hospital of the Cape Winelands (East) district  
 Diagnosis or admission during the following period: 1 November 2009 to 30 June 2010 
 
4.4.4.4 CM Audit Exclusion criteria: 
 HIV negative 
 Child (age ≤ thirteen years) 
 No CM (Indian ink and CLAT negative; CLAT titer < 1:8 on CSF) 
 Hospital clinical records unavailable 
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4.4.5 Step 5: Analysis of the data and compare results to target standards 
The researcher consulted Prof M Kidd, from Stellenbosch University’s Centre for Statistical 
Consultation (CSC), who has explained that clinical relevance (as opposed to statistical 
significance) is much more important in the audit setting. Chapter 13 (Medical audit and clinical 
governance) of the book, Research Methods and Audit for General Practice supports this 
principle: clinical relevance is the main goal of an audit. 
42 
Addendum 7 shows the data presentation format (the results of the 2008 pilot audit at Worcester 
hospital). 
Data from the audit was analysed and compared to the target standards. MS Excel was used to 
present the data in graphs.  
The researcher has also reviewed the available folders regarding ART management at Worcester 
hospitals’ infectious diseases clinic (integrated TB and HIV management). 
The cut-off date for admission of data for analysis was 9 July 2010. After this date, no new data 
was collected for analysis. 
Step 6 of the audit cycle (providing feedback to the clinical team and implement change) 
does not form part of the methods for this thesis. It will be discussed in the 
recommendations section. 
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4.5 Ethical considerations and Human Research Ethics Committee (HREC) approval 
As stated in the South African Department of Health’s Ethical Guidelines, the main 
consideration should be to conduct this clinical/medical audit in such a manner that the 
autonomy and dignity of patients with CM is respected. 
37 
This medical audit was ethically 
relevant to the patients and health professionals in the Cape Winelands (East) district, as this will 
provide a cyclical review process to improve the quality of care received by CM patients. 
Patients with AIDS and CM represent a vulnerable group of individuals. The researcher and the 
audit team were fully aware of this fact. Proper respect for the patient’s autonomy by obtaining 
informed consent prior to inclusion into the audit was a challenging situation. Informed consent 
implies that the patient should have full mental capacity as an adult. In some patients with CM, 
informed consent was not feasible: CM implies that the central neurological system is infected, 
which may result in impairment of higher functions and consciousness level. Furthermore, as this 
was an audit process that reviewed the effects of implementing clinical guidelines based on 
international evidenced-based recommendations, these patients received only the recommended 
standard medical treatment. No placebo or alternative management options were considered. 
Patients were included and excluded into the audit based on unbiased clinical criteria. Each case 
received a unique CM Audit number in the data capturing sheets. This ensured complete 
confidentiality and personal data protection. 
Therefore, the researcher applied to the ethics committee for a waiver of informed consent. There 
was no disadvantage to the patients or their relatives that would compromise their rights and 
dignity to an extent unreasonable and unjustified in terms of the benefits of the medical audit. 
Hospital Managers/Superintendents and the Director of the Cape Winelands Health District gave 
their custodian consent for the audit. The study protocol (research proposal 2010 RP 89) has 
been approved by the District Health Services and Health Programmes, Provincial Government 
of the Western Cape. 
The Health Research Ethics Committee (HREC) of the Faculty of Health Sciences, Stellenbosch 
University, approved the study protocol on 8 December 2009 (Ethics Reference no: 
N09/08/205). (See Addendum 1: Letter of Approval from HREC committee) 
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5. Results:Cryptococcal Meningitis (CM) Audit: Cape 
Winelands (East) District  
The data is presented in the following sequence: demography, analysis of management 
process and comparison of level of performance. 
Demography of Study Population 
5.1 Study Population 
5.2 Demographics of patient study population (all patients, as well as individual hospitals) 
Analysis of Cryptococcus Meningitis Management Process 
5.3 Spinal Manometry Data 
5.4 Amphotericin B Data 
5.5 Data on Patient Deaths 
5.6 Renal monitoring whilst on Amphotericin B 
5.7 ART referral Data 
Comparison of Level of Performance 
5.8 Comparison of Level of Performance to Target standard (total patient study 
population) 
5.9 Comparison of Level of Performance: Level 1 vs. Level 2 hospitals 
5.10 Comparison of Level of Performance: Worcester Regional Hospital: Pilot Audit (2008) 
vs. Re-Audit (2010) 
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5.1 Study Population 
Based on the inclusion and exclusion criteria the following patient folders were excluded. 
Table 2: Original NHLS-generated list of patient folder numbers 
(NHLS = National Health Laboratory Service) 
55 
Exclusion:  HIV (Human Immunodeficiency Virus) negative status of patient 5 
 False Positive CLAT (Cryptococcal Latex Agglutination Test) 
test (according to clinical records) on CSF (Cerebrospinal Fluid) 
4 
 Negative CLAT test (CLAT titer < 1:8) on CSF 3 
 Cryptococcal culture positive on Pleural Fluid (not CSF) 1 
 Age ≤ thirteen years (all had CLAT titer < 1:8) 6 
 Discharged prior to CLAT result available, lost to follow-up  
(not admitted for inpatient care) 
3 
 Patient self-discharged (refused hospital treatment) 1 
 Hospital clinical records not available 2 
 Duplication of folder numbers (patients had a CLAT test at one 
hospital, but were transferred to a different hospital within the 
same district for further inpatient care) 
3 
 Patient transferred to another hospital within another district for 
further inpatient care 
2 
New Total: Patient folders included in this audit (N = study population) N = 25 
 
It is important to note that Montagu Hospital had no CM patients as inpatients during the data 
collection period. 
Furthermore, N (total number of cases identified as the representative study population for 
inclusion in the medical audit) fluctuates. The number of cases was less in certain sub-sections of 
the results analysis (for example, the number of patients exposed to Ampho B is less than N). 
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5.2 Demographics of total patient study population 
Twenty-five patient folders were included in the study population. The CD4 (Cluster of 
Differentiation 4) count is provided as cells per μL (microliter) or mm3 (cubic millimeter). Three 
patients had documented previous episodes of CM. All three cases where treated with 
Amphotericin B. Management of suspected CM IRIS (Immune Reconstitution Inflammatory 
Syndrome) was not evaluated in this audit. Twenty percent of the study population was already 
on Anti-Retroviral Therapy (ART) at the time of CM diagnosis. 
Table 3a: Demographics of the total study population 
 
 
 
 
 
ALL PATIENTS Male Female Total 
Number of Patients in 
Audit 
13 12 25 
Average Age (years) 40 33 37 
Average CD4 count at 
CM diagnosis 
131 82 108 
Average inpatient stay, if 
available (in days), for 
those patients that were 
discharged 
40 28 34 
Number of Patients with 
previous diagnosis of CM 
2 1 3 
Number of Patients 
already on ART at CM 
diagnosis 
3 2 5 
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The demographic data from each hospital is presented in Table 3b. 
Table 3b: Demographics of the total study population (per hospital) 
 
The average inpatient stay in Brewelskloof hospital (BH), a specialised tuberculosis 
hospital, is expected to be above average, as these cases are admitted for inpatient 
tuberculosis management in sub-acute beds. Due to the increased incidence of HIV and 
tuberculosis co-infection, opportunistic infections (such as CM) occur in the BH patients. 
 
 
 
 
PER HOSPITAL BH CH RH WH Total 
Number of Patients in 
Audit 
5 3 3 14 25 
Average Age (years) 39 32 46 35 37 
Average CD4 count at 
CM diagnosis 
113 121 89 108 108 
Average inpatient stay, if 
available (in days), for 
those patients that were 
discharged 
84 24 16 26 34 
Number of Patients with 
previous diagnosis of CM 
1 1 1 0 3 
Number of Patients 
already on ART at CM 
diagnosis 
3 1 1 0 5 
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5.3 Spinal Manometry Data (Figure 7 and Table 4) 
Data regarding the process of spinal manometry is presented in figure 7. Patients 4, 6, 8, 11 and 
16 had no recorded data in the clinical notes regarding this management criterion (20 % of the 
study population). 
 
Eleven patients (44 % of the study population) had spinal manometry with the initial (diagnostic) 
lumbar puncture (LP). 95% had a raised intracranial pressure (ICP) reading with any LP during 
the inpatient treatment period. Ten of the eleven patients with initial spinal manometry readings 
had opening pressures greater than 20 cmH2O (raised ICP). Patient 21 had an initial opening 
pressure of 15 cmH2O (ICP not raised), but required five further manometry measurements 
during the admission period.  
 
 
Figure 7 
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Table 4: Spinal Manometry N = 25 (100 %) 
1. Spinal manometry at diagnosis (with initial LP) 11/25 patients = 44 % 
2. Patients who had at least one measurement during 
inpatient stay 
20/25 patients = 80 % 
3. All patients with manometry measurements, who had 
at least one elevated reading (equal or greater than 20 
cmH20) 
19/20 patients = 95 % 
4. No documented measurements found in clinical 
records 
5/25 patients = 20 % 
 
5.4 Amphotericin B Data (Table 5 a-b, Figure 8) 
Five patients (20%) of the study population were not exposed to Amphotericin B (Ampho B) 
treatment. Of the remaining twenty patients, 9 patients (45 %) managed to reach the target of 
fourteen days on Ampho B. An unexpected finding was the interruption of treatment due to no 
Ampho B stock. Three patients (15 %) had their Ampho B treatment interrupted due to Ampho B 
associated renal toxicity. 
Table 5: Amphotericin B Data 
a. Patient data eligible for analysis of Ampho B 
treatment process 
Total Breakdown 
Total Patient Files / Clinical records 25  
    
Exclusion (non-exposure to Ampho B or current inpatient) 5  
Inpatient Death prior to start of Ampho B  3 
Prior renal impairment (Ampho B contra-indicated)  1 
Exclusion : Current inpatient status (Ampho B in progress)  1 
    
Inclusion (exposure to Ampho B) 20  
Completion of 14 day Ampho B course  9 
Interruption due to Inpatient Death whilst on Ampho B  3 
Interruption due to No Ampho B Stock  5 
Interruption due to Ampho B related renal impairment  3 
 
Patient 17 was an inpatient at the time of data analysis. 
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b. Reasons for Patients who did not reach the  
14 days course Amphotericin B target: 
Number of patients 
No Amphotericin B stock available 5 
Death as inpatient *see separate table (below) 3 
Ampho B associated renal impairment 3 
Total 11 
 
Table 5b’s data (Reasons for not reaching the 14 day Ampho B target) is displayed in the pie 
chart below (Figure 8). 
 
 
 
 
 
Figure 8 
*Refer to Table 6 
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5.5 Data on Patient Deaths 
Table 6 looks at patients’ death in the context of Amphotericin B (Ampho B) treatment, which 
represents the main component of inpatient medical treatment. The middle column of table 6 
describes those patients who did not complete the Ampho B due to inpatient death. 
Table 6: Patients who died prior, during and post-Amphotericin B 
Died as inpatient prior to 
start of Ampho B course 
(Reason for delay to treatment 
in brackets) 
Died as inpatient during 
Ampho B course 
(Duration of Ampho B 
treatment in brackets) 
Died after completion of 
Ampho B 
(Duration between end of 
Ampho B course and patient 
death in brackets) 
Patient 11 
(Diagnosis of CM and patient 
death on the same day) 
Patient 2 (1 day) 
(Did not complete course due 
to death) 
Patient 8 (Died post-discharge 
from hospital) 
Patient died 4 months after 
discharge from hospital; co-
infection with disseminated 
tuberculosis; not on ART at 
time of death) 
Patient 18 
(Died the evening after having 
been admitted for Ampho B 
treatment: convulsion and 
focal neurology preceded 
death) 
 
 
Patient 22 (4 days) 
(Did not complete course due 
to death) 
Patient 14 (Died as inpatient) 
(Died 10 days after 
completion of Ampho B due to 
chest infection and 
bicytopenia; not on ART at 
time of death)  
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Table 6: Patients who died prior, during and post-Amphotericin B 
 
Died as inpatient prior to 
start of Ampho B course 
(Reason for delay to treatment 
in brackets) 
Died as inpatient during 
Ampho B course 
(Duration of Ampho B 
treatment in brackets) 
Died after completion of 
Ampho B 
(Duration between end of 
Ampho B course and patient 
death in brackets) 
Patient 20 
(Died 1 day after positive 
CLAT result: Ampho B 
prescribed but patient died 
before receiving 1
st
 dose) 
 
Patient 25 (1 day) 
(Did not complete course due 
to death) 
Patient 21 (Died as inpatient) 
(Died 4 days after completion 
of Ampho B; cause of death 
unclear from clinical notes; 
not on ART at time of death) 
 
Patient 7 (8 days) 
Ampho B treatment was 
interrupted due to no 
Ampho B stock; the patient 
died two days later as 
inpatient. 
Patient 23 (Died as inpatient) 
(Died 1 day after completion 
of Ampho B; cause of death 
unclear from clinical notes; 
not on ART at time of death) 
3 4 4 
 
Patient not included in this table (not treated with Amphotericin B): Patient 4 was not 
started on Ampho B due to previous renal impairment (Ampho B was contra-indicated). 
In summary, twelve patients (48% of the study population) died and eleven patients (44%) did 
not reach the two-month post-diagnosis target (patient 8 died four months after discharge). 
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5.6 Renal (Urea, Creatinine and Electrolytes) monitoring whilst on Ampho B 
Criterion 2.7 looked at the average number of Urea, Creatinine and Electrolytes (U&E and Mg) 
tests whilst on Amphotericin B (initial and 2 tests/week). 
 
During the standard fourteen-day Amphotericin B treatment period, the audit team would like to 
see an average of five U&E and Mg tests performed on each patient (one initial value and two 
tests per week, if no abnormal findings – with abnormal test results, the tests should be 
performed more often). 
 
Therefore, by the end of week one, three tests should have been done and by the end of week 
two, five tests should have been done. 
 
Figure 9: Adequacy of number of U&E tests whilst on Ampho B  
(All patients exposed to Ampho B, excluding one patient who was an inpatient at time of 
data analysis and two patients with no record of U&E tests; one patient received 17 days of 
Ampho B) 
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The unexpected finding was that patient 23 was exposed to seventeen days of Ampho B. A 
closer look at the clinical notes revealed that this patient was exposed to two different doses of 
Ampho B durung this period and that the minimum standard of renal monitoring was not met. 
The patient died one day after completion of Ampho B. The exact cause of death was unclear 
from the clinical notes. 
The Ampho B course of patients 3, 6 and 10 was stopped due to Ampho B related renal 
impairment. Patients 6 and 10 did not meet the minimum standard of renal monitoring. 
According to the clinical records, these patients did receive saline pre-loading prior to the daily 
Ampho B dose. One could, however, argue that adhering to the standard of renal monitoring may 
have enabled the clinical team to identify renal function deterioration sooner and increased the 
intravenous fluids. Unfortunately, the data capturing tool did not record the Creatinine values of 
the U&E tests done. This may have provided the researcher with an improved ability to interpret 
the results (if the Creatinine value had doubled, the SA HIV Clinician guidelines recommend the 
omission of one dose of Ampho B). 
Table 7: Adherence to minimum standard of renal monitoring whilst on Ampho B 
Minimum standard = three tests for first seven days and five tests for fourteen days 
 Number of Patients 
Adherent to minimum standard 8 
Not Adherent to minimum standard 10 
 
Of those patients where the course of Ampho B was interrupted due to Ampho B related renal 
impairment: in two out of three patients there was adherence to the minimum standard. 
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5.7 ART Referral Data 
Table 8 explains why certain folders were excluded from the evaluation of Anti-Retroviral 
Treatment (ART) referral process. Those patients already on ART, inpatients (at time of data 
analysis) and patients who died as inpatients, were excluded from the analysis. The researcher 
wanted to evaluate the patients who were in the fourteen-day inpatient period, in which the 
guidelines recommend referral for ART counselling and assessment. 
 
Table 8: ART Referral Data 
Patient data eligible for analysis of ART referral process Total Breakdown 
Total Patient Files / Clinical records 25  
    
Exclusion: 14  
Inpatient Death prior to and whilst on Ampho B  9 
Patients already on ART at time of CM diagnosis  2 
Current inpatient status (2 patients have completed Ampho 
B) 
 3 
    
Inclusion: 11  
Inpatient Death after 14 day Ampho B completion  3 
Inpatient care: alive until discharge date  7 
Patient previously on ART, but who has defaulted treatment  1 
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5.8  Comparison of Level of Performance to Target Standard for Total Study 
Population 
The following table represents the calculation process of the actual level of performance of each 
criterion for the whole study population. This level is compared to the target standard.  
Table 9a: Comparison of Level of Performance to Target Standard (N = Total Population) 
Criteria: Value 
Target 
Standard 
Actual 
Performance 
Structure 
1.1 Availability of Amphotericin B  Five patients’ Ampho B interrupted 
due to no stock 
(twenty patients on Ampho B) 
Therefore: 15/20 = 75% 
100% 75% 
1.2 Availability of Fluconazole 100% 100% 100% 
1.3 Protocol for the administration of 
Amphotericin B in the two wards 
One hospital inadequate display of 
posters in ward 
Therefore: 4/5 hospitals = 80% 
100% 80% 
1.4 Consistent Availability of Formal 
Spinal Manometers 
2/5 hospitals = 40% 80% 40% 
Process 
2.1 CT scan if depressed Level of 
Consciousness/Focal Neurology 
2/2 patients who met criteria = 
100% 
100% 100% 
2.4 Requesting CLAT on Indian ink-
negative CSF samples 
8/25 patients: Indian ink negative 
All eight patients had CLAT test 
done = 100% 
100% 100% 
CSF Manometry 
2.2 Use of CSF manometry in initial 
LP’s 
11/25 = 44% 100% 20% 
2.3 Follow-up Manometry post-CM 
diagnosis 
(= at least one reading recorded 
during admission, including 
initial LP) 
20/25 = 80% 80% 80% 
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Criteria: Value 
Target 
Standard 
Actual 
Performance 
Amphotericin B treatment process – See Table 5a 
(excluding one current inpatient, one patient with prior renal impairment  
and three inpatient deaths prior to start of Ampho B; therefore twenty patients were exposed to Ampho B) 
2.5 Completing target of fourteen 
days of IV Amphotericin B  
9/20 = 45% 80% 45% 
2.6 Using correct dose of Ampho B 
(1mg/kg) 
19/20 = 95% 100% 95% 
2.7 Adherence to minimum standard 
of renal monitoring: Average 
number of U&E, Mg tests whilst 
on Ampho B 
(two patients had no recorded 
data in records) 
8/18 adherent to minimum 
standard =  
Target standard  
Three tests for first seven days and 
five tests for fourteen days 
See Figure 8 
100% 44% 
2.8 Saline preload prior to daily 
Ampho B dose 
Two patients: No;  
One patient: No data 
Therefore: Yes/recorded in 17/20 
patients = 85% 
100% 85% 
2.9 Saline IV flush after daily 
Ampho B dose (sparsely 
documented – challenge to 
interpret) 
Three patients: No;  
Five patients: No data 
Therefore: Yes in 12/20 patients = 
60% 
100% 60% 
ART work-up process 
2.10 Referral for inpatient ART 
counselling  
(at any time during admission) 
See Table 8 
9/11 = 81%  
80% 81% 
 Number of inpatient ART 
counselling sessions (not for 
audit purposes) 
Thirteen sessions for eleven 
patients  
(minimum 0 and maximum 5) 
Average = 1.2 sessions/patient 
  
2.11 Referral to ART clinic on 
discharge 
Excluding twelve who died as 
inpatient 
Therefore: 8/8 = 100% 
 
100% 100% 
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Criteria: Value 
Target 
Standard 
Actual 
Performance 
Consolidation phase of CM treatment process (including those patients previously on ART) 
2.12 High dose Fluconazole for eight 
weeks (consolidation phase) 
Excluding eleven who died as 
inpatient,  
one patient who died within 
eight weeks post discharge, 
one patient less than two 
months post discharge at time 
of audit 
three inpatients at time of data 
analysis, 
two patients: no data available 
Therefore: 7/7 = 100% 
100% 100% 
Outcome 
3.1 Commencement of ART by week 
four into antifungal treatment 
At CM diagnosis: 20/25 were 
not on ART 
(including 1 treatment 
interrupter) 
Of these 20: 
Two were inpatients at time of 
data analysis 
Twelve died as inpatient 
One patient had no available 
data 
Therefore: 3/5 = 60% 
80% 60% 
3.2 Morbidity: incidence of Ampho B 
associated renal impairment  
Three documented cases that 
were significant enough for 
the treating team to stop 
course of Ampho B 
3/20 = 15% 
<20% 15% 
3.3 Morbidity: Ampho B associated 
thrombophlebitis 
Two documented cases:  
2/20 = 10% 
<10% 10% 
3.4 Two month-survival post-diagnosis 
Three were inpatients at time of data 
analysis 
Four patients: no data available 
 
Eleven died as inpatient 
One patient died after 
discharge 
Six patients alive two months 
post-diagnosis 
Therefore: 6/18 = 33% of 
patients alive two months 
after CM diagnosis 
60% 33% 
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Table 9b 
Comparison between the Target Standard and the Actual Level of Performance 
(total study population) 
The criteria that meet the target standards are displayed in green and those that require 
improvement are highlighted in red. 
Criteria 
Meeting 
Target Standard 
NOT Meeting 
Target Standard 
Structure 1.2 Availability of Fluconazole 1.1 Availability of Amphotericin B  
  1.3 Protocol for the administration of 
Amphotericin B in wards 
  1.4 Availability of Spinal 
Manometers 
Process 2.1 CT scan if depressed Level of 
Consciousness/Focal Neurology 
2.2 Use of CSF manometry in all 
initial LP’s 
 2.4 Requesting CLAT on Indian 
ink-negative CSF samples 
2.5 Completing target of fourteen 
days of IV Amphotericin B 
 2.3 Follow-up Manometry post-
CM diagnosis when raised OP 
with initial LP or symptoms of 
raised ICP 
2.7 Adherence to minimum standard 
of renal monitoring 
 2.6 Using correct dose of Ampho 
B (1mg/kg) 
2.8 Saline preload prior to daily 
Ampho B dose 
 2.10 Referral for inpatient ART 
counselling 
2.9 Saline IV flush after daily 
Ampho B dose 
 2.11 High dose Fluconazole for 
eight weeks (consolidation phase) 
 
 2.12 Referral to ART clinic on 
discharge 
 
Outcome 3.2 Morbidity: incidence of 
Ampho B associated renal 
impairment  
3.1 Commencement of ART by week 
four into antifungal treatment 
 3.3 Morbidity: Ampho B 
associated thrombophlebitis 
3.4 Two month-survival post-
diagnosis 
Stellenbosch University  http://scholar.sun.ac.za
52 
 
5.9  Comparison of Level of Performance: Level 1 vs. Level 2 hospitals 
The data of six Level 1 and fourteen Level 2 patients were used to look at the differences in 
structure, process and outcome in the management of CM. Level 1 refers to Ceres (CH) and 
Robertson (RH), whilst Level 2 refers to Worcester (WH). The researcher excluded the data from 
Brewelskloof (BH) for this analysis, as the average length of stay for these patients were 
considerably longer, as they were treated for complicated tuberculosis in sub-acute beds in a 
dedicated tuberculosis hospital. 
The data is presented in the same format: demography, analysis of management process and, 
finally, comparison of level of performance between the two levels of hospital care. 
Table 10: Comparison of Level of Performance: Level 1 vs. Level 2 hospitals 
 
Table 10a: Demographics Level 1 Level 2 
Number of Patients in Audit 6 14 
Average Age (years) 39 35 
Average CD4 count at CM diagnosis 105 108 
Average inpatient stay, if available (in days), for 
those patients that were discharged 
20 26 
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Table 10b. Results: Level of Performance: Level 1 vs. Level 2 
Criteria: 
Target 
Standard 
Actual Performance 
Level 1 Level 2 
Structure 
1.1 Availability of Amphotericin B  
100% 
One patients’ 
Ampho B 
interrupted due to 
no stock 
Therefore: 5/6 = 
83% 
One patients’ 
Ampho B 
interrupted due 
to no stock 
Therefore: 6/10 
= 60% 
1.2 Availability of Fluconazole 100% 100% 100% 
1.3 Protocol for the administration of 
Amphotericin B in wards 
100% 
2/2 hospitals = 
100% 
0/1 = 0% 
1.4 Consistent Availability of Formal 
Spinal Manometers 
80% 
0/2 hospitals = 
0% 
1/1 = 100% 
Process 
2.1 CT scan if depressed Level of 
Consciousness/Focal Neurology 
100% 100% 100% 
2.4 Requesting CLAT on Indian ink-
negative CSF samples 
100% 
1/6 patients: 
Indian ink 
negative 
This patient had 
CLAT test done = 
100% 
3/14 patients: 
Indian ink 
negative 
3/3 patients 
had CLAT test 
done = 100% 
CSF Manometry 
2.2 Use of CSF manometry in initial 
LP’s 
 
100% 1/6 = 17% 5/14 = 36% 
2.3 Follow-up Manometry post-CM 
diagnosis 
(= one reading recorded during 
admission) 
80% 3/6 = 50% 13/14 = 93% 
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Criteria: 
Target 
Standard 
Actual Performance 
Level 1 Level 2 
Amphotericin B treatment process 
2.5 Completing target of fourteen days 
of IV Amphotericin B  
 
80% 2/5 = 33% 5/11 = 45 % 
2.6 Using correct dose of Ampho B 
(1mg/kg) 
 
100% 5/5 = 100% 10/11 = 91% 
2.7 Adherence to minimum standard of 
renal monitoring (initial and 
two/week) 
 
100% 
2/5 Adherent  
= 40 % 
4/9 Adherent  
= 44% 
2.8 Saline preload prior to daily Ampho 
B dose 
100% 
One patients: No 
Yes recorded in 
4/5 patients = 
80% 
One patient: 
No; One 
patient: No 
data 
 Yes recorded 
in 9/11 patients 
= 81% 
2.9 Saline IV flush after daily Ampho B 
dose 
100% 
3 patients: No;  
Therefore: Yes in 
2/5 patients = 
40% 
1 patients: No; 
5 patients: No 
data 
Therefore: Yes 
in 5/11 patients 
= 45% 
ART work-up process: Eligibility criteria similar to district study population evaluation 
2.10 Referral for inpatient ART 
counselling  
(at any time during admission) 
 
80% 3/3 = 100% 5/7 = 71% 
 Number of inpatient ART 
counselling sessions (not for audit 
purposes) 
 
1 session for 3 
patients 
(minimum 0 en 
maximum 1) 
Average = 0.3 
sessions/patient 
6 sessions for 5 
patients 
(minimum 0 en 
maximum 2) 
Average = 1.2 
sessions/patient 
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Criteria: 
Target 
Standard 
Actual Performance 
Level 1 Level 2 
2.12 Referral to ART clinic on discharge 
100% 
Excluding three 
who died as 
inpatient 
Therefore: 3/3 = 
100% 
Excluding 
twelve who 
died as 
inpatient and 
two currently 
inpatient 
Therefore: 5/5 
= 100% 
Consolidation phase of CM treatment process (including those patients previously on ART) 
2.11 High dose Fluconazole for eight 
weeks (consolidation phase) 
100% 
Excluding two 
who died as 
inpatient,  
one patient who 
died within eight 
weeks post 
discharge, 
Therefore: 3/3 = 
100% 
Excluding 
seven who died 
as inpatient,  
two inpatients 
at time of data 
analysis, 
two patients: 
no data 
available 
Therefore: 3/3 
= 100% 
Outcome 
3.1 Commencement of ART by week 
four into antifungal treatment 
80% 
At CM diagnosis: 
4/6 were not on 
ART 
Of these four: 
One died as 
inpatient 
Therefore: 1/3 = 
33% 
At CM 
diagnosis: 
14/14 were not 
on ART 
(including 1 
defaulter) 
Of these 
fourteen: 
two were 
inpatients at 
time of data 
analysis 
seven died as 
inpatient 
one patient has 
no available 
data 
Therefore: 2/6 
= 33% 
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The eligibility criteria for evaluating the Ampho B treatment process were similar to total study 
population evaluation.
Criteria: 
Target 
Standard 
Actual Performance 
Level 1 Level 2 
3.2 Morbidity: incidence of Ampho B 
associated renal impairment  
20% 
Two documented 
cases that were 
significant enough 
for the treating 
team to stop 
course of Ampho 
B 
2/5 = 40% 
Zero 
documented 
cases that were 
significant 
enough for the 
treating team to 
stop course of 
Ampho B 
0/11 = 0% 
3.3 Morbidity: Ampho B associated 
thrombophlebitis 
 
10% 
Zero documented 
cases: 0/5 = 0% 
One 
documented 
case: 1/11 = 
9% 
3.4 Two month-survival post-diagnosis 
60% 
Zero were 
inpatients at time 
of data analysis 
0 patients: no data 
available 
Two died as 
inpatient 
One patient died 
after discharge 
Three patients 
alive two months 
post-diagnosis 
 
Therefore: 3/6 = 
50% of patients 
alive two months 
after CM 
diagnosis 
Two were 
inpatients at 
time of data 
analysis 
Three patients: 
no data 
available 
Seven died as 
inpatient 
Zero patient 
died after 
discharge 
Two patients 
alive  two 
months post-
diagnosis 
 
Therefore: 2/9 
= 22% of 
patients alive 
two months 
after CM 
diagnosis 
Performance meeting target standards Performance not meeting target standard 
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5.10 Comparison of Level of Performance: Worcester Regional Hospital:  
Pilot Audit (2008) vs. Re-Audit (2010) 
The findings of the two audits at Worcester hospital are compared. 
Table 11a. Demographics: Worcester Hospital Audits (2008 and 2010) 
 
Table 11b. Comparing of actual performance of WH (2008 vs. 2010) to the target standards  
Table 11a. Demographics 2008 2010 
Number of Patients in Audit 13 14 
Average Age (years) 35 35 
Average CD4 count at CM diagnosis 110 108 
Average inpatient stay, if available (in days), for 
those patients that were discharged 
No data 26 
Number of Patients on with previous diagnosis of 
CM 
2 0 
Number of Patients already on ART at CM 
diagnosis 
3 0 
Criteria (from the pilot audit) 
Level of 
Performance 
Actual 
Performance: 
2008 
Actual 
Performance: 
2010 
Structure 1.1 Availability of 
Amphotericin B 
100% 100% 60% 
 1.2 Availability of 
Fluconazole 
100% 100% 100% 
 1.3 Protocol for the 
administration of 
Amphotericin B in ward 
100% 50% 0% 
Process 2.4 Requesting CLAT on 
Indian ink-negative CSF 
samples 
100% 100% 100% 
 2.7 Baseline U&E and 
biweekly U&E 
100% 92% 44% 
 2.1 CT scan if depressed 
Level of 
Consciousness/Focal 
Neurology 
100% 75% 100% 
Stellenbosch University  http://scholar.sun.ac.za
58 
 
 
 
 
 
Criteria (from the pilot audit) 
Level of 
Performance 
Actual 
Performance: 
2008 
Actual 
Performance: 
2010 
Process: 
continued 
2.2 Use of CSF manometry in 
all LP’s 
100% 23.1% 
Initial LP: 
36% 
Follow-up 
Manometry: 
93% 
 2.5 Completing target of 
fourteen days of IV 
Amphotericin B 
80% 77.8% 45% 
 2.12 High dose Fluconazole 
for eight weeks 
(consolidation phase) 
100% 100% 100% 
  Adherent to long-term 
Fluconazole (secondary 
prophylaxis) 
80% 71.4% 
Not 
measured 
 2.13 Referral to ART clinic 100% 100% 100% 
 3.1 Commencement of ART 
by week four into 
antifungal treatment 
 
80% 0% 33% 
Outcome 3.2 Morbidity: incidence of 
drug-induced renal 
impairment 
(Amphotericin B) 
20% 
0 – 15% 
(i.e. <20%) 
0% 
 3.4 Two month-survival post-
diagnosis 
60% 46.2% 22% 
Performance showing 
improvement and meeting 
target standard 
Performance showing 
improvement, yet still not 
meeting target standard 
Performance worse than 
previous audit and not 
meeting target standard 
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6. Discussion of Results 
 
The results are evaluated in light of the literature reviewed. Furthermore, it is essential to 
evaluate if the objectives of the audit were met. The results are discussed in three sections: the 
total study population, the comparison of the Level 1 vs. Level 2 hospitals and the comparison of 
the pilot audit (2008) vs. re-audit (2010) at the regional hospital. 
 
6.1 Total Study Population (N = 25) – Cape Winelands (East) District 
The two sections of findings are illustrated in green (areas of good practice: meeting target 
standards) and in red (areas in need of improvement: not meeting target standards). 
 
6.1.1 Areas of good practice: 
Only one structure-related criterion, the availability of Fluconazole, was sufficient (criterion 1.2). 
In terms of process, CT scans were ordered when indicated (criterion 2.1). The clinical team was 
aware of the need to perform CSF manometry (criterion 2.3) once the diagnosis of CM was 
made. CLAT tests were ordered on Indian ink negative CSF samples (criterion 2.4). The correct 
dose of Ampho B was prescribed (criterion 2.6) and inpatients were referred for ART 
counselling (criterion 2.10). On completion of the Ampho B course, patients were started on high 
dose Fluconazole (consolidation phase) (criterion 2.11) and, on discharge, patients were referred 
for follow-up at the ART clinic (criterion 2.12). 
The outcome-based criteria, renal impairment (criterion 3.2) and thrombophlebitis (criterion 3.3) 
associated with Ampho B treatment, were within acceptable levels (literature-based target 
standards were achieved). 
 
 
Performance meeting target standards Performance not meeting target standard 
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6.1.2 Areas in need of improvement: 
The availability of Amphotericin B, spinal manometers and ward protocols were inconsistent 
(criteria 1.1, 1.3 and 1.4). An unexpected finding was the interruption of treatment due to no 
Ampho B stock. The researcher has conducted an informal interview with the main pharmacist. 
It seems that there may be a delay when ward staff fail to order stock in time. This issue needs 
further exploration at local and regional Pharmaceutical Treatment Committee (PTC) meetings. 
There was a paucity of spinal manometry measurements with initial lumbar punctures (criterion 
2.2). Reasons for non-adherence to this criterion require analysis. The fishbone diagram (Figure 
10) examines possible causes in the following categories: Equipment and Materials, Process, 
Environment, People/Staff and Management. A comprehensive approach is required to address 
the multi-factorial issues regarding this criterion, especially the issue of staff-turnover (interns 
and junior medical officers rotate through departments). 
The guidelines recommend subsequent manometry measurements in those patients who had a 
raised reading. It may be speculated that clinical factors such as absence of raised ICP signs and 
absence of headache may have influenced the treating doctor to withhold follow-up manometry 
measurements. 
Reasons for failing to reach the fourteen-day Ampho B target (criterion 2.5) were highlighted in 
the pie chart (Figure 8). There were three main reasons: patient death, drug stock problem, renal 
impairment. The monitoring of Ampho B treatment was also sub-optimal. Reasons for failing to 
attain the minimum number of U&E tests (criterion 2.7) require exploration. Possible causes for 
sub-standard renal monitoring include location of laboratory services and awareness of need to 
monitor renal function. The NHLS laboratory is located adjacent to Worcester hospital. Access 
to laboratory services after-hours is a potential problem at the district hospitals. However, a 
courier service collects laboratory specimens twice a day (during office hours) at each district 
hospital. 
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Figure 10: Cause and Effect Fishbone Diagram           
Failure to perform or document spinal manometry with initial lumbar puncture (LP) in patients with 
Cryptococcal Meningitis (CM) 
         
  Cause           Effect   
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Process 
 
People / Staff 
    
           
           
  
No formal spinal 
manometers available 
 
Failure to perform spinal 
manometry with initial 
diagnostic LP  
Lack of knowledge or 
experience of the 
treatment guideline     
           
       Regular staff-turnover     
     
Failure to document 
opening pressure in 
clinical records 
 
Limited or absent skills 
experience with the 
spinal manometry 
technique     
            
  
 
 
 
 
  No spinal 
manometry with 
diagnostic LP 
  
          
  
No formal spinal 
manometers available 
 
Possible limited support 
for quality care of CM 
and HIV  
Failure to order spinal 
manometers 
    
           
    
Possible HIV stigma and 
cultural influences 
 
Failure to identify 
low/absent stock during 
stock control     
           
    
Possible failure to 
incorporate evidence-
based medicine in clinical 
practice       
  Materials  Environment  Management     
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Saline preload prior to Ampho B dose (criterion 2.8) and saline flushing of line after Ampho B 
dose (criterion 2.19) requires renewed emphasis (including the need to emphasise the importance 
of documenting these steps of the management protocol). These criteria were poorly documented 
in the clinical notes. 
The challenge to start patients with CM on ART within four weeks from onset of antifungal 
treatment (A2A period = Ampho to ART period), seems to be an ongoing one (criterion 3.1). A 
cause and effect Fishbone diagram may be of use to evaluate causality. 
The two-month survival figure of CM patients is still below the Sub-Sahara reference value 
(criterion 3.4) – this will warrant further exploration. Factors that predict higher mortality should 
guide the clinical team in directing more attention to guideline-based care. These negative-
predictive factors regarding mortality-risk include high CSF fungal burden, raised intracranial 
pressure, low CD4 count and other co-morbid factors. 
43 
6.2 Comparison Level 1 and Level 2: 
 
The researcher needs to emphasise the small size of the study population. Furthermore, there are 
important differences between the package of care of Level 1 (generalist-led care) and Level 2 
(specialist-led care). However, there are certain themes that may be examined in the correct, non-
judgmental light: the two levels of care represent a continuum of care in one district and both 
services depend on each other. The following themes describe the clinical relevance of the audit 
findings: 
Spinal manometry (process) is performed more consistently in the Level 2 hospital than in the 
Level 1 hospitals; spinal manometers (structure) are also consistently available at the Level 2 
hospital. Spinal manometers were introduced to the sub-district management and procurement 
departments of the district hospitals prior to the audit period (this intervention coincided with the 
teaching activities). However, the manometers were not readily available at the district hospitals. 
The clinical use of the manometers (by doctors) and stocking of manometers (management and 
procurement department) need to be re-emphasised.  
Performance meeting target standards Performance not meeting target standard 
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The adherence to renal monitoring of patients on Ampho B (U&E, Mg) is lacking in both 
settings and fails to meet the target standard. At Level 1, access to laboratory services is 
comparable to the Level 2 hospital during office-hours (when U&E tests are typically done), as a 
courier service collects laboratory specimens twice a day at each district hospital. Saline 
preloading is done well in both settings, however saline flushing of the line after the Ampho B 
dose is poorly documented in both settings. The importance of clear and complete clinical record 
keeping should be addressed with the next intervention. 
The inpatient referral for ART counselling is more consistent in the Level 1 setting, however 
both levels of care have difficulty in achieving the target of four weeks between onset of Ampho 
B and onset of ART. The barriers to this process require further analysis (ART work-up, social 
assessment and other factors may need consideration). 
Both settings report a low prevalence (over the data collection period) of Ampho B related 
morbidity (but documentation of these side-effects were consistently sparse in both settings). 
The two-month survival figure fails to meet the target standard in both settings; there has been a 
worsening in survival at Level 2 compared to the pilot audit in 2008 (discussed in the next 
section). 
In summary, this comparison between the two levels of care makes it possible to recommend that 
Level 1 hospitals continue to manage CM patients. The availability and use of spinal 
manometers, and closer adherence to renal monitoring will support this recommendation. 
Arrangement of inpatient ART counselling happened more consistently at the Level 1 hospital. 
Adherence to the ART target and measures to prevent Ampho B related morbidity is comparable 
to that of the Level 2 hospital. 
6.3 Comparison Pilot Audit (2008) vs. Re-Audit (2010) at Level 2 hospital (Worcester): 
The table demonstrates the findings in the “traffic light” colour scheme:  
 
This visual guide is an effective way to inform the audit team (and reader) of areas of good 
Performance showing 
improvement and meeting 
target standard 
Performance showing 
improvement, yet still not 
meeting target standard 
Performance worse than 
previous audit and not 
meeting target standard 
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practice and areas for improvement. The colour orange/yellow is used to highlight those areas 
that have improved, but are still not meeting the target standards. 
Of interest is the similarity between the demographics of the two audit groups (age and CD4 
count): see Table 11a. 
In terms of structure, the availability of Ampho B stock has been inconsistent during the re-audit 
period. This represents a new (and unexpected) finding. As mentioned, this issue requires further 
exploration at local and regional Pharmaceutical Treatment Committee (PTC) meetings. 
The availability of a ward-based CM treatment protocol (poster and guidelines) have been 
lacking in both audits. Surprisingly, this occurred after the researcher has distributed laminated 
posters with treatment guidelines (Addendum 6) together with the teaching intervention. 
In terms of process, the attention to renal monitoring in Ampho B exposed patients has decreased 
in the re-audit period. This is likely to be a multi-factorial based problem that needs to be 
addressed during the feedback phase to the audit team. 
The re-audit has shown an improvement in adherence to the CT scan indication standard. This 
may be attributed to the acquirement of a CT scanner at Worcester hospital during the data 
collection period. 
The overall attention to spinal manometry has improved considerably in the re-audit period; the 
adherence to the use of manometry with the initial (diagnostic) LP needs to be re-addressed. 
The re-audit period has shown a decline in achieving the fourteen-day Ampho B goal. As 
mentioned, this was likely to be caused by the Ampho B stock issue and the higher mortality rate 
in the re-audit group. 
There has been an improvement in reaching the four-week Ampho B to ART goal. The factors 
that led to this improvement (clinical significance) require exploration, identification and re-
enforcement. Similarly, the worsening of the two month-survival post-diagnosis figures needs 
exploration to identify possible correctable causes (clinical management factors, health care 
provider factors, patient factors and health system factors). The process of continuous quality 
improvement involves re-enforcement of what is done well and intervention in what is done 
poorly. 
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6.4 SWOT Analysis of Audit experience 
The researcher has experienced the continuous learning curve that is essential with any project of 
this size. A SWOT analysis is a “strategic planning method used to evaluate the Strengths, 
Weaknesses, Opportunities, and Threats involved in a project.” 44 This process will help to 
evaluate the audit. 
 Strengths 
o The audit team consisted of key individuals at each hospital. The researcher 
maintained contact with the rest of the team via face-to-face meetings (individual 
and group), telephonic conversations and email communication (see Addendum 8 
for an example of such an email). The importance of teamwork was highlighted. 
o Partnership and interaction with NHLS laboratory: the researcher enjoyed good 
support, especially in terms of obtaining the list of folder numbers that were 
coupled with CM tests during the audit period. 
 Challenges and Pitfalls (Weaknesses) 
o The prospective data collection process failed, especially at Worcester hospital: 
no data capturing forms were completed at Worcester during the audit period. The 
researcher was aware of this problem and attempted to remind the clinical team of 
the audit process. This has led to under-reporting of cases. In the future, 
alternative data collection processes should be explored. 
o The challenge of collecting data in patients transferred to different hospitals, 
especially to hospitals outside district: these cases were excluded, as they were 
managed at hospitals that were not included in the audit. 
o At Worcester hospital, the ward where most of the CM patients were treated, 
struggled to provide continuity of care. This proved to hamper the audit process 
(adherence to guidelines and data collection). Factors that had a negative 
influence included staff factors (regular staff turnover and level of 
seniority/experience) and structural factors (no CM management posters and no 
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CM Audit documents were found on inspection). The level of 
seniority/experience of the treating doctor may possibly influence the adherence 
to the CM treatment steps. It should also be noted that the teaching intervention 
was held at the end of the calendar year. New interns and community service 
doctors (junior doctors) started to work at both Level 1 and 2 hospitals in January 
2010. The researcher discussed the option of a follow-up teaching intervention 
with the audit team, but it was suggested that the audit champions of each hospital 
should orientate the new doctors regarding the CM audit process (treatment 
guidelines and data capturing forms). 
o Clinical records: as mentioned, some notes were incomplete and this hampered 
the team’s ability to analyse the data. 
o The unexpected finding of the Ampho B stock shortage needs attention in the 
feedback process and planning of the next intervention. 
o Also unexpected was the finding that three patients were discharged from the 
casualty department prior to CSF CLAT result availability (the researcher has 
contacted the clinical team and a follow-up review of these patients was 
arranged). CLAT tests take three to five days. Therefore, an improved follow-up 
system should be arranged on discharge with the primary care or ART clinic (if 
the patient meets discharge criteria). Local discharge criteria require review. 
o The issues of spinal manometer availability and adherence to manometry have 
been explored. Alternative options of measuring raised ICP were employed: crude 
opening pressures were measured with regular intravenous lines; this is a non-
standardised and inaccurate way of measuring the opening pressure. It may 
provide and estimate of raised ICP and the need for a therapeutic tap to relieve 
such pressure. However, the gold standard remains a standardised spinal 
manometer (cheaper models are available that may match the costs of intravenous 
lines). Possible supply chain issues of procurement should be explored. 
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 Opportunities 
o This audit has the inherent ability to improve CM care and outcome, reduce 
Ampho B-related morbidity and improve access to ART. 
o If implemented and continued correctly, with the necessary buy-in and support of 
stake-holders, a culture of quality awareness may be created. This may lead to 
further audits and QI initiatives in various aspects of care. 
 Threats 
o Lack of resources (including human resources, time and management support) 
may hamper the process of establishing a culture of quality improvement. 
o Failure to re-audit the management of CM in HIV adults in the Cape Wineland 
(East) district, may lead to a missed opportunity to address the gaps identified by 
this audit. 
 
6.5 Possible Confounding factors 
The following factors should be considered during the evaluation of the audit findings 
 The influence of the teaching intervention may be confounded by the annual change-over 
of clinicians: a new set of doctors replaced some of the doctors at the beginning of the 
calendar year (new interns and community service doctors). The formal teaching 
interventions were held during September and October of 2009. Clinical guidelines were 
available in the wards and senior doctors were present at the teaching sessions. The new 
set of doctors may have previous clinical experience of the management of CM.  
 The adequacy of clinical record keeping (doctors and nurses) in certain folders has made 
it challenging to audit the criteria. 
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6.6 Discussion of Quality Improvement tools 
The most important part of the audit is the ability to enable change. The change process involves 
three stages: 
1. Initiation (change analysis: stakeholder analysis: enabling buy-in) 
2. Implementing change (action plan: intervention) 
3. Continuing the process (re-audit to confirm improvement). 6 
 
Various Quality Improvement tools/instruments (with the common goal of closing the gap 
between evidence-based medicine and routine practice) have been described. The audit team will 
need to consider new strategies when planning the intervention. A list of six general categories is 
provided, but usually a multi-modal approach is required: 
1. provider education 
2. provider reminder systems and decision support 
3. audit and feedback 
4. education of patients 
5. organisational change 
6. financial incentives, regulation, and policy 
 
The key features of an effective strategy for improving care are: 
 an active strategy 
 a multifaceted/multimodal approach 
 a continuous process of improvement 
The application of these principles in enabling change, will be discussed in the 
recommendations. 
Figure 11 provides an example of a multimodal QI strategy: this multimodal strategy was 
aimed at improving venous thromboembolism (VTE) prophylaxis, based on the Joint 
Commission/ National Quality Forum (NQF)-endorsed consensus standards. (Abbreviations in 
Figure: ACCP - American College of Chest Physicians; ICS - International Consensus 
Statements; IUA - International Union of Angiology; QI - quality improvement; RAMs - risk 
assessment models)
 45 
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Figure 11: Example of a multimodal QI strategy 
45 
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7. Recommendations 
 
The recommendations will be discussed in two sections: those recommendations for future 
cycles of the CM audit; and, recommendations for audits in general, specifically in the public 
health sector of South Africa. 
 
7.1 Recommendations for future cycles of CM audit process: 
A dedicated audit team with clear task delegation is required at each site. Each setting should 
explore ways to encourage buy in and empowerment of health care workers. 
7.1.1 Feedback Phase of Audit and Feedback QI instrument: 
The researcher is planning formal feedback sessions to the audit team and the health care 
workers at the hospitals involved. 
A meta-analytic study has explored the applicability of the Feedback Intervention Theory (a 
framework from industrial/organizational psychology) in health care Audit and Feedback. One 
example of how feedback may be maximally effective, is the emphasis that the recipient should 
be focused on the task. Frequent, individualised, and non-punitive feedback has been shown to 
be effective in helping primary care providers adhere to clinical practice guidelines. 
46 
 
7.1.2 Next step of the cycle: considering a new intervention 
An Integrated Clinical Pathway (iCP) may improve the clinical team’s management approach by 
providing a clear systematic treatment plan for each patient admitted with CM: 
“(Integrated care pathways) are multidisciplinary, locally agreed, evidence-based plans, 
describing the expected progress of a specific patient group. They form all or part of the 
clinical record. By facilitating the evaluation of outcome, they can be a quality improvement 
tool for use as part of clinical governance.” 47 
 
Such an iCP should be based on the SA HIV Clinician Society guidelines and the recently 
published 2010 IDSA (Infectious Diseases Society of America) CM management guidelines. 
19, 
48
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It has been shown that a strategy that involves developing and disseminating local hospital 
guidelines may be more effective than passive dissemination of national or international 
guidelines. 
24 
iCPs have resource implications: all new staff will require induction. Current staff 
will require ongoing training. 
47 
The researcher has composed a draft iCP (Addendum 10), which will be presented to the clinical 
and audit team for discussion and approval.
 
The iCP incorporates the audit criteria, which may 
streamline future follow-up audits (re-audits). The iCP may enable the team to keep a CM data 
base/ data register.  
While the iCP acts as a template of the care to be provided to the chosen group of patients, it is 
not intended to compromise clinical judgment. Members of the clinical team may deviate from 
the pathway if there is a valid reason. Analysis of variations from the pathway provides 
information to the clinical team on the overall quality of care and helps to identify any trends that 
may require further investigation. iCPs are dynamic documents: change is to be expected as new 
evidence and clinical guidelines emerge. 
49 
 
7.1.3 Review of the steps of the Audit Process 
The audit team should review the factors that influenced the steps of this audit. It is clear that 
close liaison with the NHLS Laboratory is essential. 
An iCP may augment the clinical notes and facilitate the data capturing process of the individual 
criteria (this will address the issue of paucity of clinical notes). 
Aspects of Structure, especially Spinal Manometers, need to be re-addressed prior to 
commencing a further audit cycle: liaison with the supply chain (procurement involvement) of 
the hospital administration and hospital management will be essential. 
A CM database or data register (with the aid of the Laboratory, ART clinic and iCP) may enable 
the audit team to improve the quality of data for subsequent audits. This database may also be 
utilised for other forms of research (with the necessary ethics committee approval), such as long 
term follow-up, evaluation/audit of adherence to Fluconazole and/or ART, the incidence of CM 
IRIS and CM Fluconazole resistance. 
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7.1.4 CM prevention (primary prevention) 
Ultimately, a primary prevention/screening approach should be envisaged, compared to the 
standard curative approach. The focus should be on primary prevention and exploring the 
reasons (social and cultural) why patients present to health institutions in the advanced stages of 
HIV/AIDS and opportunistic infections. 
The TB/HIV service integration within the primary health care system (and acceptance of 
HIV/AIDS as a chronic illness) may enable this paradigm shift. 
The following aspects of care need support: 
 Screening for HIV in patients: early access to diagnosis and CD4 count, early ART to 
prevent low CD4 and risk of Opportunistic Infections. 
 Early diagnosis of CM: its atypical presentation warrants high index of suspicion. 
 Attention to best practice care during A2A (Ampho B until ART) period has greatest chance 
on survival to ART initiation. 
Renewed focus and energy aimed at educational interventions should be aimed at both health 
care workers and the public. 
7.2  Recommendations for future audits (in general) in public sector hospitals 
The central question should be posed: Who should be responsible for quality improvement? 
(“Whose job is it”): employer vs. employee vs. public? Ultimately, all stakeholders should be 
involved in the process. 
A culture of Quality Improvement should be created and maintained. 
28 
Hospital Accreditation with Health Quality Assurance organisations (such as the Council for 
Health Service Accreditation of South Africa, COHSASA) should be pursued, as this may create 
the necessary external motivation to conduct QI initiatives. 
50 
The employer should make participation in QI activities part of health care workers’ job 
description (an institutional intervention, as opposed to other forms of non-regulatory 
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incentives). This regulatory intervention is common in first world health systems, where 
institutional, regional and national audit support and development organisations are in place. 
The audit teams may choose to adapt target standards and levels of performance to constraints 
faced in public health system. A balance should be sought between realistic and appropriate 
target standards, compared to unacceptable, sub-standard targets. 
Interventions should focus on the essentials of good care (“Back to basics”): start with CQI 
initiatives at PHC level and focus on key areas (HIV, TB, chronic disease burden, health system 
improvement, equal health access). Parallel, interdisciplinary programmes should address the 
social determinants of health: health education, addressing crime and interpersonal violence, 
addressing unemployment and poverty, basic education, capacity development, community 
orientated care and upliftment. 
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8. Conclusions 
This thesis represents a follow-up medical audit on the adherence to management guidelines of 
Cryptococcus Meningitis (CM) in the Cape Winelands (East) district, Western Cape, South 
Africa. This re-audit follows on a teaching intervention based on the findings of a pilot audit in 
2008 at the Level 2 hospital. The audit team reviewed cases diagnosed and treated between 
November 2009 and June 2010. Twenty-five folders were reviewed. The clinical (not statistical) 
significance of the audit findings is relevant in order to achieve change in practice. 
The teaching intervention aimed to increase awareness of the importance of spinal manometry 
in diagnosing and treating raised intracranial pressure (ICP), given the strong association 
between CM and raised ICP. Furthermore, the intervention stressed the need to commence early 
ART counselling in order to achieve the four week goal (period between commencement of 
Amphotericin B and start of ART). 
The 2010 audit highlighted the following areas that are in need of improvement and that should 
be the focus of a new set of intervention strategies: 
 Amphotericin B (Ampho B) stock availability 
 Renal function monitoring of patients on Ampho B treatment 
 Emphasis on the importance of completing the fourteen day Ampho B treatment period: 
the potentially avoidable factors that prohibit completion during this audit were Ampho B 
stock shortage and Ampho B associated renal impairment. 
 Improved medical record keeping of both doctors and nurses: this audit has shown that 
certain aspects of the treatment process were documented poorly: saline preload and 
flushing the line with saline after each Ampho B dose are key examples. 
 Commencement of ART by week four into antifungal treatment. 
 Awareness of the high mortality level of the CM patients studied in this audit.  
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In terms of the quality of care of Level 1 vs. Level 2 hospitals, some important conclusions may 
be made: 
Level 1 hospitals should continue to manage CM patients. The availability of spinal manometers 
and closer adherence to renal monitoring will improve the chance of achieving target standards. 
Arrangement of inpatient ART counselling happened more consistently at the Level 1 hospital. 
Adherence to the ART target and measures to prevent Ampho B related morbidity is comparable 
to that of the Level 2 hospital. 
The comparison of the 2008 pilot audit findings with those of the 2010 re-audit at Worcester 
hospital showed an increased use of spinal manometry (however, the current practice needs to 
improve in order to meet the target standards). Patient survival has declined. Ampho B stock 
shortage was an unexpected non-adherent finding. The process of continuous quality 
improvement involves re-enforcement of what is done well and intervention in what is done 
poorly. 
The audit has also provided insight to the researcher and audit team on the practical challenges of 
conducting a prospective data collection technique across different care settings (five hospitals: 
three Level 1 district hospitals, one regional sub-acute tuberculosis hospital and one Level 2 
secondary hospital). The buy-in of stakeholders (management, health care workers and patients), 
the ongoing support of an audit team and a committed Quality Improvement environment will 
make the medical audit process feasible and care improvement possible. 
Formal feedback to the clinical team and management is planned. A multimodal interdisciplinary 
Quality Improvement approach (such as an integrated care pathway) is recommended and a 
future re-audit is important to monitor improved adherence to the CM management guidelines. 
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Addendum 2 
The Minute Paper: Feedback from Teaching Intervention 
30 October 2009, Worcester Hospital 
Please spend one minute on the following question (Answers are kept anonymous): 
Regarding the management of Cryptococcus Meningitis patients: which aspect of your 
management of these patients will change after today’s discussion? 
Summary of Participant Responses: 
 Manometry and therapeutic CSF drainage: 
o Management of raised ICP: 
 “Managing symptomatic CM: daily LPs” 
 “Asymptomatic: LPs every 2 – 3 days” 
o Early referral to neurosurgery 
 Amphotericin B:  
o No longer test dose needed  
o Management of adverse reactions: 
 Saline preload before Ampho B administration (helps to prevent renal 
side-effects) 
 Flushing drip after Ampho B administration (helps to prevent 
thrombophlebitis) 
 Follow-up: 
o “Will ensure adherence to secondary Fluconazole prophylaxis” 
o “Will attempt early referral for ART” 
o “Confirm referral to ART clinic – personally” 
 General: 
o “Many steps changed – learned a lot” (Ampho B administration; ART referral) 
o “Will think of CM as number one cause in HIV patient with meningitis 
symptoms” 
o “This workshop was a fantastic, practical bridge from academic knowledge 
(rather faded) to the practical management of CM patients – please do this again: 
the other interns could also use this.” 
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Addendum 3 
Data Capturing Sheet: Cryptococcal Meningitis Medical Audit 
Cape Winelands District (East) (2009 – 2010) 
Please complete all areas (if possible) for each adult patient (> 13 years of age) admitted and diagnosed 
with Cryptococcal Meningitis (CSF Indian Ink and/or CLAT test positive). 
All data will be used confidentially (use only the patient’s file number). Encircle options provided where 
applicable. Kindly use clear handwriting. Forms are available in electronic format. 
Please contact the Principal Investigator, Dr Klaus B von Pressentin, with any queries: 023-626 8040; 
email: klausvonp@gmail.com. Your help with this audit is appreciated and will contribute to 
improved service delivery and awareness about Cryptococcal Meningitis. 
1 Hospital / Ward 
 
 
2 CM Audit Number: Please contact Dr Von 
Pressentin to obtain Number (eg CMA 02) 
 
3 Age 
  
4 Sex 
 
Male Female 
5 Date admitted 
 
 
6 Date discharged 
 
 
7 RVD status 
 
 
8 CD4 count 
 
 
9 Indian Ink result  
10 CLAT result / titre 
 
 
11 Previous CM diagnosis 
 
Yes No 
12 Already on ART at time of CM diagnosis?  Yes No 
13 CT scan if indicated: depressed level of 
consciousness / focal neurology/ seizures 
 
14.a.  Use of CSF manometry 
(measurement of opening 
pressure): 
 
(Answer Yes/No and please provide 
measurement values in cmH20 of 
each measurement done, where 
applicable) 
At diagnosis   
14.b. Number of 
Follow-up CSF 
manometry 
measurements 
 
Page 1 of 2 
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15 Dose of Ampho B used (mg/kg)  
16 Completing target of 2 weeks of IV Ampho 
B (if No: provide number of days administered) Yes 
No 
Days: 
17 Saline pre-loading before daily Ampho B 
dose 
Yes No 
18.a. 
Monitoring of U&E, Mg while on Ampho B 
Yes No 
18.b. Number of U&E, Mg tests done while on 
Ampho B 
 
19 Saline flush of IV line after Ampho B dose 
(daily) 
Yes No 
20 Thrombophlebitis at IV line site? Yes No 
21.a. Referral for ART counselling (as inpatient) Yes No 
21.b. Number of ART counselling sessions 
received as inpatient 
 
22 ID clinic appointment made (on discharge) Yes No 
23.a. Commencement of ART within 1 month 
(from start of antifungal treatment) Yes No 
23.b. Date of ART commencement  
24 High dose Fluconazole for 8 weeks Yes No 
26 2 month-survival post-discharge Yes No 
27 Date of death (if applicable)  
28 
Cause of Death (if applicable) 
 
 
 
 
 
 
 
 
List of Abbreviations:  
Ampho B = Amphotericin B; 
ART = Anti-retroviral Treatment;  
CLAT = Cryptococcal Latex Agglutination Test 
CSF = Cerebrospinal Fluid;  
CT = Computer Tomography;  
ID clinic = Infectious Diseases clinic 
IV = Intravenous;  
RVD = Retroviral Disease;  
U&E, Mg = Urea and Electrolytes, Magnesium 
This medical audit has been approved by the Health 
Research Ethics Committee of the Faculty of Health 
Sciences, Stellenbosch University:  
Ethics Reference no: N09/08/205. 
This audit will be used by the audit team to improve the 
health care of CM patients. The results will be used 
towards a thesis for an M Med degree in Family Medicine 
at Stellenbosch University (Supervisor: Prof HH 
Conradie). 
Page 2 of 2 
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Addendum 4 
Patient Register: Cryptococcal Meningitis Medical Audit 
Cape Winelands District (East) (2009 – 2010) 
 
Hospital: ……………………………………………………… 
Number CMA Number Admission 
date 
Discharge date 
(if applicable) 
Date of Death 
(if applicable) 
ART clinic 
appointment 
date 
1 
 
 
     
2 
 
 
     
3 
 
 
     
4 
 
 
     
5 
 
 
     
6 
 
 
     
7 
 
 
     
8 
 
 
     
9 
 
 
     
10 
 
 
     
Contact Person: Dr Klaus von Pressentin: 023-626 8040; klausvonp@gmail.com 
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Addendum 5: Cover document for data capturing sheet and patient register 
Cryptococcal Meningitis Medical Audit 
Cape Winelands District (East) (2009 – 2010) 
Cryptococcus Meningitis Mediese Oudit 
Kaap Wynland Distrik - Oos (2009 – 2010) 
A Medical Audit of the management of Cryptococcal Meningitis (CM) in HIV patients in the 
Cape Winelands (East) District, Western Cape, South Africa. 
Introduction: 
 Cryptococcal Meningitis (CM) remains a leading cause of mortality in AIDS patients in 
developing countries.  
 Effective treatment of increased intracranial pressure (present in at least 50% of cases) 
can improve outcome.  
 The first 2 weeks of antifungal treatment are the most important phase of the treatment of 
CM, as this period could have the biggest impact on outcome.  
 ART should ideally be started within 2 – 4 weeks of start of antifungal treatment for CM. 
Aims and objectives of the Audit: 
The aim of this medical audit (Quality Improvement Cycle) is to improve the treatment of 
Cryptococcal Meningitis (CM) in HIV-patients in the eastern part of the Cape Winelands District 
(Witzenberg, Breede Valley, Langeberg municipalities), and to improve the clinical team’s 
awareness of and adherence to national treatment guidelines. 
The objectives of the audit on the quality of care for CM in Level 1 and 2 hospitals are: 
a. To create appropriate target standards  
b. To demonstrate an improvement in the quality of care at the Level 2 hospital 
c. To identify strengths and weaknesses at Level 1 and Level 2 hospitals 
d. To identify key interventions that may improve the quality of care  
e. To reflect on the quality of care at Level 1 vs. Level 2 hospitals 
f. To provide feedback to the facilities and department of health 
Contact Principal Investigator, Dr Klaus von Pressentin, with any queries:  
Tel: 023-626 8040; email: klausvonp@gmail.com . 
Ethics Reference no: N09/08/205 (HREC, Faculty of Health Sciences, Stellenbosch University) 
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Praktiese Riglyne t.o.v. die Oudit-proses 
 Data-insameling periode: November 2009 - Junie 2010 
 
 Watter pasiënte? 
 
Alle volwasse HIV-positiewe pasiënte gediagnoseer met Cryptococcus Meningitis kwalifiseer 
(ouderdom >13 jaar). 
 
 Hoe werk die vorms? 
 
1. Data insamelingsvorm (Data Capturing Sheet) 
(2 bladsye - kan op 'n enkele A4 bladsy aan weerskante afgerol word) 
Voltooi in duplikaat: 
 Een kopie bly in die pasiënt se leêr 
 Ander kopie vergesel die pasiënt na die ART kliniek. 
Die idee is dat die data insamelingsvorm met die ontslagvorm voltooi word op die dag 
van ontslag.  
(Vul asb ook ‘n vorm in op die dag van sterfte, indien van toepassing) 
 
Uiteindelik sal die vorms in die ART kliniek versamel word.  
 
2. CMA nr (CM Audit nr): Bel asb Dr K von Pressentin met ontslag/sterfte om ‘n Oudit 
nommer vir elke pasiënt te verkry. Hierdie CMA nr moet in plek van die leërnommer op alle 
data insamelingsvorms verskyn. Hierdie is noodsaaklik vir vertroulikheidsredes. 
 
3. Pasiënt Register 
 
Hou asb 'n data register in die sale, waar die pasiënt se oudit nommer (CMA nr), opname en 
ontslag datum en ART-kliniek datum ingevul kan word. Indien moontlik, faks/epos asb. ‘n 
kopie van die opgedateerde register elke maand aan my (faks: 023-626 1727). 
 
4. Hou al die vorms in 'n leêr in die sale, sodat dit byderhand is as die pasiënt ontslaan 
word. 
Die waarde van die oudit proses kan tweeledig beskryf word: 
1. Review of clinical decision making and management 
2. Making the most efficient use of resources for the patients 
(van "Medical audit: Rationale and practicalities" deur SP Frostick et al (editors) ) 
 
Uiteindelik is die oudit proses die gevolg van 'n spanpoging om gelyke kwaliteitsorg aan alle 
pasiënte in die plaaslike gesondheidstelsel te bewerkstellig. 
Kontak gerus die navorser, Dr Klaus von Pressentin, met enige navrae:  
Tel: 023-626 8040; epos: klausvonp@gmail.com . 
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 Addendum 6: CM Management Poster (SA HIV Clinician Society) 
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Addendum 7 
 
Summary of the Pilot Audit results at Worcester Hospital, 2008 
 
Comparing actual performance to the target standards 
 
Criteria  Level of 
Performance 
Actual 
Performance 
Structure Availability of Amphotericin B  100% 100% 
 Availability of Fluconazole 100% 100% 
 Protocol for the administration of 
Amphotericin B in ward 
100% 50% 
Process Requesting CLAT on Indian ink-
negative CSF samples 
100% 100% 
 Baseline U&E and biweekly U&E 100% 92% 
 CT scan if depressed Level of 
Consciousness/Focal Neurology 
100% 75% 
 Use of CSF manometry in all LP’s 100% 23.1% 
 Completing target of 14 days of IV 
Amphotericin B 
80% 77.8% 
 High dose Fluconozole for 8 weeks 
(consolidation phase) 
100% 100% 
 Adherent to long-term Fluconazole 
(secondary prophylaxis) 
80% 71.4% 
 Referral to ART clinic 100% 100% 
 Commencement of ART by week 4 
into antifungal treatment 
80% 0% 
Outcome Morbidity: incidence of drug-
induced renal impairment 
(Amphotericin B) 
20% 0 – 15%  
(i.e. <20%) 
 2 month-survival post-diagnosis 60% 46.2% 
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Comparing actual performance to the target standards (continued) 
 
Criteria Meeting 
Target Standard 
NOT Meeting 
Target Standard 
Structure Availability of 
Amphotericin B 
Protocol for the 
administration of 
Amphotericin B in ward 
 Availability of Fluconazole  
Process Requesting CLAT on 
Indian ink-negative CSF 
samples 
Baseline U&E and 
biweekly U&E 
 Completing target of 14 
days of IV Amphotericin B 
CT scan if depressed Level 
of Consciousness/Focal 
Neurology 
 High dose Fluconozole for 
8 weeks (consolidation 
phase) 
Use of CSF manometry in 
all LP’s 
 Referral to ART clinic Adherent to long-term 
Fluconazole (secondary 
prophylaxis) 
  Commencement of ART 
by week 4 into antifungal 
treatment 
Outcome Morbidity: incidence of 
drug-induced renal 
impairment (Amphotericin 
B) 
2 month-survival post-
diagnosis 
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Addendum 8 
Communication with the Audit Team  
An (unedited) example of  an email sent to the audit team by the researcher 
(Audit Lead) 
“28 Junie 2010 
Aan: CM Audit Champions, Kaap Wynland Oos 
Beste kollegas 
Hoop dit gaan goed! 
Ons is nou in die finale peilvlak van die CM oudit en die data-insameling periode eindig 30 Junie 
2010. 
Ek wil nou weereens jou (as “audit champion”) hulp vra met die nagaan van die data 
insamelingsvorms deur op die volgende paar kwessies te let in die komende week: 
1.    Verseker asb dat alle data registrasie vorms bymekaar versamel word in die komende week. 
2.    Gaan asb die meegaande lys deur wat ons met die NHLS se hulp saamgestel het (alle 
positiewe CM toetse – dit onderskei ongelukkig nie tussen HIV positiewe en HIV-negatiewe 
gevalle nie; verder is die lys se periode langer as dié van die oudit: November 2009 – vandag, 28 
Junie 2010). Trek asb die addisionele leêrs (indien nodig) en konsulteer asb met die 
ARV/infeksiekliniek om die data ivm ARVs in te samel. 
3.    Ek beplan om tussen 5-7 Julie die rondte te doen om by elk van die 5 “sites” te doen om die 
data vorms in te samel en om ‘n kort onderhoud met julle te doen ivm jul ervaring van die oudit 
proses. Laat weet asb wanneer dit julle die beste sal pas – ek sal julle gedurende die komende 
week persoonlik bel om ‘n tyd af te spreek! 
Ek is baie dankbaar vir jul hulp tot dusver! Ek is ook opgewonde oor die data-lys vanaf die 
NHLS lab – ek wil asb die beroep op almal doen om deurgaans alle data en inligting as 
vertroulik te hanteer. Ek herinner julle ook aan die gees van nie-diskriminasie van die mediese 
oudit-proses/kwaliteitsverbeteringsiklus: geen hospitaal of individuele gesondheidswerker sal 
onregverdig gekritiseer word nie.  
‘The aims of this process are: 
1.    to audit the audit process: identifying pitfalls and challenges in the audit process in a multi-
site audit, with special consideration of the challenges faced in the public health sector with 
limited resources (time, human resources, staff changeover, IT constraints, medical records) 
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2.    to audit the management of CM, with consideration of challenges faced in the secondary vs. 
district hospital setup. (Medical audit: Rationale and practicalities)’ 38 
Ek dink ons is besig met waardevolle werk – hierdie oudit en meegaande dinkskrum sal goeie 
voorstelle bied vir die distrik en sub-distrik besture, aangesien medies oudits deel is van die 
gesondheidsorg spektrum se toekoms, veral noudat konsepte soos “clinical governance, 
accountability and continuous quality improvement” alledaags raak. Die oudits itv chroniese 
siektes is ‘n goeie voorbeeld van hierdie nuwe tendens. 
Ek verwelkom julle terugvoer. 
Groete, Klaus” 
Addendum 9: Detailed Quality Improvement Cycle 
NICE: Principles for Best Practice in Clinical Audit (2002) 
25 
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Addendum 10: Draft Document: Integrated Care Pathway 
 
Draft document (Nr 1: August 2010) 
I n t e g r a t e d  C a r e  P a t h w a y  
Management of Cryptococcal Meningitis  
in immune-suppressed Adults (Age > 13 years) 
Cape Winelands (East) District 
Western Cape, South Africa 
 
This document should be completed for every patient diagnosed and admitted with 
Cryptococcal Meningitis at the following hospitals:  
 Worcester hospital 
 Brewelskloof hospital 
 Ceres hospital 
 Montagu hospital 
 Robertson hospital 
 
This document should be seen as a clinical record that is kept in the patient’s folder.  
 
All information should be kept confidential. 
 
This is a guideline of best practice for the multidisciplinary team treating a patient 
admitted with Cryptococcal Meningitis. All actions/care must be signed for daily or 
a variance recorded if there is a deviance from the planned care. The pathway will 
be used for clinical audit purposes. 
 
This document was prepared by Dr Klaus B von Pressentin, August 2010 
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Admission Record 
Hospital  
Ward  
Patient Name (use label if available)  
Patient Sex  
Folder Number  
Date of Birth / Age  
Address  
Date of Admission  
Date of Amphotericin B commencement  
Date of Discharge / Death  
Date of transfer to another hospital 
(if applicable; please document name of hospital and 
reason for transfer) 
 
Date of ART commencement  
ID clinic follow-up appointment date  
RVD status  
CD4 count  
Indian ink result  
CLAT result / titre  
Previous CM diagnosis?  
 
Evidence-base of Integrated Care Pathway 
McCarthy K, Meintjes G, guideline writing committee. Guidelines for the prevention, diagnosis 
and management of Cryptococcal Meningitis and Disseminated Cryptococcosis in HIV-infected 
patients. S Afr J HIV Med. 2007;Spring:18-23. 
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Schematic overview of Integrated Care Pathway 
1. Consider Diagnosis of Cryptococcal Meningitis (CM) in a HIV Adult 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Contra-indication to Lumbar Puncture? 
3. Lumbar Puncture and Spinal Manometry 
4. CM diagnosis confirmed 
5. First Episode of CM? 
No 
6. Standard CM Treatment Guideline 
Yes CT Brain 
Consider alternative diagnosis  
(infective and non-infective) 
Yes No 
Yes No Consider IRIS or  
Fluconazole resistance 
7. ART work-up: Already on ART? 
National ART Guidelines 
Yes No Consider ART adherence factors  
and review ART regime 
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Cryptococcal Meningitis Treatment Guidelines 
1. Consider Diagnosis of Cryptococcal Meningitis (CM) in a HIV Adult 
 headache 
 unexplained fever 
 nausea and vomiting 
 neck stiffness 
 confusion 
 seizures 
 abnormal behaviour 
 new onset psychiatric symptoms 
 altered level of consciousness 
 focal neurological signs 
 diplopia or unexplained blindness 
 coma 
 
2. Contra-indication to Lumbar Puncture? 
If focal neurological signs are present, perform a CT brain (where available) to ensure LP is safe. 
 
3. Lumbar Puncture and Spinal Manometry:  
Document Opening Pressure and Volume CSF drained 
Lumbar puncture is necessary for an etiological diagnosis. 
Therapeutic tap if Opening Pressure > 20 cmH20:  
Alleviate pressure initially by draining not more than 20 – 30 ml of CSF at initial LP  
(to decrease Opening Pressure by 20 – 50%) 
3.1 Request the following investigations routinely: 
Microscopy (cell count, Gram stain and Indian ink stain), 
Chemistry (protein, glucose), Bacterial culture (MCS); 
Cryptococcal antigen (CLAT) detection should be requested only if the Indian ink test is 
negative 
3.2 Consider the following investigations (in consultation with senior colleague): 
Smear and culture for Mycobacterium tuberculosis (requires at least 5 ml CSF), 
TPHA/VDRL for syphilitic meningitis, Toxoplasma gondii IgG and IgM. 
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4. Diagnostic Criteria for CM: 
Positive Indian ink, or CLAT positive (titer > 1:8) 
 
 
5. Treatment 
First episode of CM 
Induction Phase: 
Amphotericin B treatment (1mg/kg)  
for 2 weeks (minimum 1 week) 
 
Consolidation Phase: 
Fluconazole 400mg daily for 8 weeks 
 
Secondary Prophylaxis: 
Fluconazole 200mg daily for life  
or until CD4 > 200 cells/mm
3
 for more than 
6 months on ART  
(at least 12 months of Fluconazole in total) 
 
 
 
 
 
 
 
 
Antifungal Susceptibility Testing (AFST) 
against Fluconazole is only advised with 
recurrent CM. 
In cases of suspected Fluconazole resistance 
or suspected CM IRIS, consult with the 
Specialist Physician at Worcester hospital or 
the Infectious Diseases specialist at 
Tygerberg hospital.
 
 
 
 
 
 
 
 
 
 
Recurrent CM 
Repeat LP must be done to 
 confirm CM 
 to exclude concurrent pathology 
 to have an isolate for susceptibility testing 
 and to identify and manage raised 
intracranial pressure 
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6.1 General treatment guidelines: Amphotericin B: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.2 General treatment guidelines: Fluconazole 
 
 
1. Dose used: 1mg/kg intravenous 
2. Ampho B reconstituted in 1 liter 5% Dextrose water and administered over 4 hours 
3. No test dose required if daily dose is run slowly over the first half hour of administration 
4. Prevent Ampho B-associated renal impairment, hypokalemia and hypomagnesemia:  
a. Saline Preload Daily: 1 liter Normal Saline with 1 ampoule KCl (20 mmol) added, 
over 4 – 6 hours, prior to daily dose 
b. Avoid concurrent use of nephrotoxic medication (NSAIDs, Aminoglycocides) 
c. Monitoring of Creatinine, Potassium (K+) and Magnesium (Mg++): see Calendar 
d. If renal impairment occurs: 
i. If Creatinine increases by 2-fold or more, omit a dose and/or increase 
prehydration to 1 litre 8-hourly 
ii. If Creatinine fails to decrease after above intervention, stop Ampho B and 
use Fluconazole 
5. Treat Ampho B-associated febrile reactions: 
a. Paracetamol 1g orally 30 minutes prior to dose 
b. Severe reactions may require hydrocortisone 25mg IV at the start of the infusion 
6. Prevent Ampho B-associated thrombophlebitis:  
a. Flush line with 200ml Saline after each daily dose of Ampho B 
b. Change IV line every 2nd – 3rd day 
1. Generally well tolerated 
2. Beware of need to adjust dose according to GFR (glomerular filtration rate) and use in 
pregnant women (teratogenicity) 
3. Beware of drug interactions (Fluconazole is an enzyme inhibitor: relevant with TB 
medication and Nevirapine) 
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Induction Phase:  
Week 1 of Amphotericin B treatment 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
A
m
p
h
o
te
ri
ci
n
 B
 T
re
at
m
en
t 
Saline Preload Daily        
Ampho B dose given Daily 
(if dose omitted, provide reason and action) 
       
Document Febrile reaction (if present)        
Saline Flush of Line after daily dose 
(200ml Saline) 
       
Document drip line changed  
(change drip site every 2 to 3 days) 
       
Creatinine, K
+
, Mg
++
 twice a week  
(document values) (Days 1, 4, 7, 10, 13)
 
       
Weekly Ward Hb (Days 1, 7, 14)        
S
p
in
al
 M
an
o
m
et
ry
 
Spinal Manometry 
(in cmH20, elevated if 
reading is >20 cmH20) 
Opening 
Pressure 
       
Volume drained 
(ml) 
       
Closing Pressure 
(if possible) 
       
ART ART counselling sessions        
Inpatient Treatment Calendar: Week 1 
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Induction Phase:  
Week 2 of Amphotericin B treatment 
Day 8 Day 9 Day 10 Day 11 Day 12 Day 13 Day 14 
A
m
p
h
o
te
ri
ci
n
 B
 T
re
at
m
en
t 
Saline Preload Daily        
Ampho B dose given Daily 
(if dose omitted, provide reason and action) 
       
Document Febrile reaction (if present)        
Saline Flush of Line  
(200ml Saline after daily dose) 
       
Document drip line changed  
(change drip site every 2 to 3 days) 
       
Creatinine, K
+
, Mg
++
 twice a week  
(document values) (Days 1, 4, 7, 10, 13)
 
       
Weekly Ward Hb (Days 1, 7, 14)        
S
p
in
al
 M
an
o
m
et
ry
 
Spinal Manometry 
(in cmH20, elevated if 
reading is >20 cmH20) 
Opening 
Pressure 
       
Volume drained 
(ml) 
       
Closing Pressure 
(if possible) 
       
ART ART counselling sessions        
Inpatient Treatment Calendar: Week 2 
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7. ART work-up 
 All HIV-positive patients who develop CM are eligible for Cotrimoxazole prophylaxis 
 Recommendation by SA HIV Clinician Society Guideline Committee: 
Start ART 2 – 4 weeks after onset of antifungal treatment (ART may be started as 
inpatient) 
 Long in-patient stay is ideal for ART work-up and counselling 
 ART work-up Blood tests as per national protocol: ALT, RPR, FBC & Diff 
 ID clinic or local clinic appointment on discharge, to ensure seamless work-up and 
initiation of ART 
 ID clinic or local clinic referral letter to be completed on discharge with other discharge 
documents 
 
List of Abbreviations 
Ampho B: Amphotericin B 
ALT: Alanine transaminase 
ART: Anti-retroviral Treatment 
CLAT: Cryptococcal Latex Agglutination Test 
CSF: Cerebrospinal Fluid 
CT: Computer Tomography 
FBC & Diff: Full Blood Count and Differential 
GFR: glomerular filtration rate 
Hb: Hemoglobin 
ID clinic: Infectious Diseases clinic 
IV: Intravenous 
RPR: Rapid plasma reagin (test for syphilis) 
RVD: Retroviral Disease (Human Immunodeficiency 
Virus) 
U&E, Mg = Urea and Electrolytes, Magnesium 
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